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A number of low molecular weight (LMW) organic chemicals are known
to cause occupational respiratory or skin sensitisation. A set of 200
LMW organic skin and approximately 75 respiratory sensitisers were
identified by critical appraisal of published case literature. The respi¬
ratory sensitisers (asthmagens) were systematically compared in turn
with suitable control chemicals and the skin sensitisers using a case-
control methodology. The control chemicals were selected from known
hazardous LMW organic chemicals for which no reports of respiratory
sensitisation could be found.
Several potential methods of differentiating between asthmagens and
controls or asthmagens and skin sensitisers (by chemical structure
alone) were investigated. These comprised hazardous fragment iden¬
tification by calculating odds ratios for hazard (HOR's), cluster anal¬
ysis and the logistic regression analysis. Of these methods the most
effective approach was the logistic regression analysis. Using these
methods several known or suspected hazardous substructures were
confirmed to present statistically significant occupational asthma (OA)
hazard. These included isocyanates, acid anhydrides, acrylates and
(oligo)-amines. Furthermore, certain sub-structural fragments such as
chlorine atoms appeared to provide a protective effect from OA haz¬
ard. For differentiating between skin sensitisers and asthmagens it
was noted that fragments with carbon double bonded to nitrogen or
oxygen atoms were significantly more prevalent in the respiratory sen¬
sitisers set.
A predictive model of chemical asthma hazard was created using lo¬
gistic regression and the model tested on a validation set of chemi¬
cals yielded a predictive kappa value greater than 0.7. This model is
available for predictive testing of compounds for asthma hazard via the
World Wide Web.
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This work demonstrates that simple structural information may, in
conjunction with a well designed methodology, be used to identify occu¬
pational sensitisers with reasonable reliability.
Abbreviations
A full list of abbreviations is available in appendix D.3
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This thesis investigates the degree to which chemical structure can
be used to identify occupational sensitising hazard. A null hypothesis
which states:
The potential of a chemical to cause occupational allergic
disease cannot be predicted from structure alone.
will be applied. The acceptance or rejection of this hypothesis will be
dependent on the validity (or otherwise) of the data, the methods used
and hence the results of this study.
Moreover it was an expressed aim that, if at all possible, a working
predictive model of occupational chemical asthma hazard should be
created. In order to be a predictive system of practical application a
model should be simple to use. Throughout, this thesis attempts to
elucidate the maximum predictive information from basic topological















Figure 1.1: Two approaches to structure-activity relationship studies.
the a priori assumption that structurally similar molecules will exhibit
comparable properties [2].
Two possible approaches to studying the structure-activity relation¬
ships (SAR's) are the purely observational approach and the purely
mechanistic approach (see Figure 1.1). The mechanistic approach in¬
volves forming mechanistic hypotheses based on current knowledge, in
this case of the immunology and biochemistry ofallergy. The purely ob¬
servational approach attempts to identify associations between struc¬
tural data and activity without presuming a particular mechanism or
mechanisms. A mechanistic model assumes a causative relationship
whereas an observational model need only assume an associative rela¬
tionship. A well designed observational approach has the advantage of
being more objective as it makes fewer a priori assumptions.
In this study an observational approach was used and thus the model
may be understood in the absence of immunological mechanistic knowl¬
edge, although the findings may contribute to mechanistic hypotheses.
The use of a purely observational model is open to the criticism that
the observed associations may arrive by chance. For this reason the
use of statistics to quantify the reliability of associations arising and
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the use of a validation procedure to test the final model are crucial if
such a non-mechanistic model is to be accepted.
1.2 Epidemiology and the Study ofDiseases
The recognition of causal or determinant factors in disease is central
to the way illness is viewed and treated. People would associate their
sickness with something they had done wrong. In Biblical times dis¬
ease was seen as a consequence of sin. Indeed when healing the para¬
lytic Jesus said...
... your sins are forgiven. (Mark,2:5.)
In the the 19th Century Louis Pasteur's ideas of disease being due to
infectious agents prevailed. So when Casimir Funk suggested that the
disease beri-beri was due to a "vitamine" deficiency his ideas were not
immediately accepted [3]. However it was becoming apparent that as¬
tute observation of case histories and lifestyle of the sick could give
clues to the determinants of disease. Perhaps the finest 19th Century
example of a methodical approach to identifying disease determinants
was John Snow's work On the Mode ofCommunication ofCholera [4].
Epidemiology is the study of diseases in populations [1, pi]. It is how¬
ever more than that; it is the systematic study of determinants of dis¬
eases and the distributions of diseases within populations. In the for¬
ward to Richardson's book reprinting John Snow's work [4], Frost gives
the following description of the discipline:
Epidemiology at any given time is something more than the
total of its established facts. It includes their orderly ar¬
rangement into chains of inference which extend more or
less beyond the bounds of direct observation.
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The implication is that through an ordered approach the discipline of
epidemiology makes apparent those associations that would be hidden
from cursory view.
Epidemiology is founded on two fundamental assumptions about the
nature of disease: firstly, it assumes that disease does not occur ran¬
domly; and secondly, it assumes causal (and therefore preventive) fac¬
tors are responsible for disease. Often these factors are in the environ¬
ment.
Criteria for determining disease causation are important. In theory a
causal factor should be both necessary and sufficient to cause the effect.
In reality what is deemed 'causal' will depend on current knowledge
- at the time of Snow a particular water supply was deemed causal
without knowledge of underlying micro-organism, Vibrio cholerae. As¬
sociations alone may arise by chance so it is important to have criteria
for determining how the associative relationship might reflect a causal
relationship. Table 1.1 lists some of the criteria which should be ap¬
plied to determine causation taken from Hennekens and Buring [1],
These criteria are not absolute, if they are not all fulfilled it is possible
a causal relationship still exists. An outcome that is all or nothing1 (i.e.
occurs at a threshold) and irreversible will fail to satisfy the temporal
and the dose-response criteria.
Case-control studies are frequently used in epidemiological research
because of their relative simplicity and low cost. They often represent
the only practical methodology for studying rare diseases. The present
study can be said to implement an approach analogous to a case-control
study.
Usually a case-control study involves the identification of subjects with
the disease and control subjects selected to be representative of the
undiseased individuals. The groups are then compared in order to iden¬




Is there a valid statistical association?
- is the association likely to be due to chance?
- is the association likely to be due to bias?
- is the association likely to be due to confounding?
Can this valid statistical association be judged as cause or effect?
- is there a strong association?
- is there biologic credibility to the hypothesis?
- is there consistency with other studies?
- is the time sequence compatible?
- is there evidence of a dose-response relationship?
Table 1.1: Framework for the interpretation of an epidemiologic study.
(After Hennekens and Buring [1, Page 45, Table 3-1], though this is based
on Bradford Hill's original observations on Statistical Evidence and Inference
[5])
may be associated with the disease occurring. The method is prone to
bias in selection (of cases and controls) from the population as a whole
and bias in the identification of exposures for each of the two groups.
The case-control methodology is not suitable for identifying temporal
factors in disease aetiology but has the advantage that is considerably
cheaper than long term monitoring of a population that is required for
a cohort study.
Occupational Health And Disease
The types of factors proposed as responsible for disease have varied
across time and culture. Postulated causes for disease may include
divine retribution for one's sins or the effects of evil spirits. Such ex¬
planations were often all that was left if no obvious external cause was
available. It is perhaps inevitable (given the proportion of adult life
spent pursuing an occupation) that some disease will occur as a conse¬
quence of a person's employment. Indeed it is not difficult to imagine
the variety of occupational hazards that accompanied the development
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ofmankind through the various stages of history. Socrates is credited
with the observation
'What are called the mechanical arts...
...damage the bodies of those who work at them...'[6]
but to the ancient Greek 'citizens' occupational disease was of little
importance because it did not directly affect them [6]. Mining, one of
the most hazardous of occupations is also amongst one of the oldest. In
1556 Georgius Agricola's work De Re Metallica described in one of its
volumes the diseases, accidents and hazards particular to mining [6].
The landmark text in occupational respiratory disease was written by
Bernardino Ramazzini (De morbis artificum diatriba) in 1713 [7, 8].
According to Butcher and Salvaggio [8], Ramazzini's was the first pub¬
lished description of dyspnoea after inhalation of organic dust. Ra¬
mazzini is also described as the Father of Occupational Medicine [6]
since it was he who suggested an addition to the questions Hippocrates
recommended physicians put to their patients. That addition was to
enquire after the patient's occupation.
1.3 Allergic Disease
Immunology of Allergy
Allergic reactions are caused by an inappropriate response of the sub¬
jects immune system. Allergy is defined in the dictionary [9] as "a
hyper-sensitivity to a substance that causes the body to react to any
contact with that substance". A more immunological definition is one
that states hyper-sensitivity occurs when "immune reactions are out
of all proportion to the damage that may be caused by a pathogen"
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[10]. Similarly sensitisation is defined as the process "to make or be¬
come sensitive; to render (an individual) sensitive to a drug, aller¬
gen, etc.." A subject who is allergic/sensitised to a particular agent -
the allergen/sensitiser - will exhibit an adverse reaction to that agent
which is greatly in excess of the reaction that would be observed when
a non-allergic subject undergoes the same exposure.
Diagnosis of allergy requires a demonstration of hyper-sensitivity. To
be a true allergy the allergen must evoke in the subject a response
which is not seen in the normal population exposed to the same degree.
Furthermore this reaction must be demonstrated to be specific and not
the result of non-specific hyper-reactivity - the condition in which the
subject reacts to agents to which they may never previously have been
exposed. (In practice the distinction between non-specific and allergic
hyper-reactivity may not be clear cut [11, 12].)
Occupational allergy covers a spectrum of diseases including dermati¬
tis, conjunctivitis, rhinitis, asthma and in the most severe cases ana¬
phylaxis [13]. The pathway by which allergy occurs in an occupational
setting is typically contact or inhalation. Allergy may be caused by
sensitivity to a vast range of chemical agents. According to Hodgson et
al., the prevalences of occupational dermatitis and asthma in the U.K.
(based on self-reported symptoms) are 54,000 and 20,000 respectively
[14]. Occupational allergy therefore accounts for significant workplace
morbidity. Consequently a means of identifying novel hazardous chem¬
icals represents an opportunity to prevent further morbidity.
Immune Defences
The body can be considered to be protected from attack by infectious
agents by three forms of defence. The most obvious are the physical
barriers, the skin, the epithelial linings of the lung and the gut. These
barriers are highly effective. The second form of defence is the innate
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immune response. This is the response to cell surface markers common
to many pathogens. These responses are mediated by the complement
system. The third form of defence is the adaptive immune response - a
mechanism by which the body learns to identify and destroy pathogens.
On re-exposure to the same pathogen the response is faster and more
effective. It is this third form of defence responding inappropriately
that results in allergic disease.
Types of Adaptive Immune Responses
Adaptive immune responses are classified into one of four response
types [15, 10].
• Type I Reactions - Anaphylaxis - asthma
• Type II Reactions - Antibody-mediated cytotoxicity
• Type III Reactions - Immune complex disease
• Type IV Reactions - Cell-mediated immune reactions - dermatitis
Of these, Types I and IV are the most important with respect to allergy
and will be described in more detail in the following sections. Type II
reactions include auto-immune responses. Blood cells are an example
of the cell targets of Type II reactions which result in the lysis and
phagocytosis of these cells. Type III reactions occur when antibody-
antigen complexes form at a critical intermediate size (smaller, soluble
complexes can readily be cleared and larger complexes can be removed
by the reticuloendothelial system). The intermediate complexes how¬
ever aggregate around the basement membranes triggering inflamma¬
tory mediator release. An example of a Type III reaction would be
the serum sickness observed when a heterologous serum transfusion is
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given. Types II & III (hyper-sensitivity) reactions are not believed to
be relevant in allergic reactions.
Although the immune system has some innate (non-specific) defence
mechanisms (such as complement formation and phagocytosis) those
mechanisms involved in allergy are the result of adaptive immune re¬
sponses. In particular, this includes the recruitment of antibodies (also
known as immuno-globulins (Ig's)) which can specifically recognize for¬
eign molecules (antigens) and bind to them. Antibodies are proteins
which may be schematically represented as Y'-shaped molecules. The
arms of the Y' are the binding regions, two per molecule, and the stem
is known as the constant region. Once antibody has bound antigen,
that antigen is marked as an appropriate target for an immune re¬
sponse. This response may include the stimulation of memory cells,
the release of inflammatory mediators or the recruitment ofphagocytic
cells.
Many of the agents that cause occupational asthma are low molecular
weight chemicals. Low molecular weight chemicals may not be true
antigens. More typically they may be haptens - molecules which in
isolation are too small to be immunologically recognized. Haptens only
become recognized by antibodies after conjugation to another molecule,
typically a host protein (see Figure 1.2). The hapten-protein conjugate
is recognised as foreign by the host immune system and an immune
response results. Various studies [16] have shown that haptens need
to bind in relatively large numbers to host proteins to produce effec¬
tive antigenic conjugates. It has been suggested that OA is mediated
through a Type I immune response [17] and while this may be true for
the majority of cases there may be exceptions [18],
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Figure 1.2: Antigen formation.
Type I (Hyper-sensitivity) Reactions - Anaphylaxis
Usually the term allergy is used to refer to Type I (immediate hyper¬
sensitivity) immune reactions. Type I reactions are extremely rapid, an
example being the immediate wheal and flare seen on the skin of hay
fever suffers when scratch tested with pollen extracts. Type I reactions
account for the majority of cases of asthma. The term anaphylaxis is
also used to describe Type I reactions, particularly the more severe
ones in which there is constriction of smooth muscle, vasodilation and
a very real risk of death.
Type I reactions are mediated by the antibody/immunoglobulin (Ig)
IgE. Antibodies (immunoglobulins) are protein molecules which pos¬
sess an ability to recognise and bind to other molecules. Reaginic an¬
tibodies (reaginins) are cytophyllic antibodies produced in response to
allergen. The term reaginic is more commonly encountered in the older
literature. Reaginic antibodies refer to the E class of immunoglobulin,
IgE and to a lesser extent the G class, IgG.
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IgE antibody is found in serum and attached to FCeRI receptors on
mast cells. These receptors bind to what is known as the constant
region of the IgE antibody (the stem of the eY). In serum the half life of
IgE is only a few days but IgE bound to FCeRI receptors on mast cells
may last for many months [10]. Normal levels of serum IgE are in the
range 10 to 200 IU/ml (median ~100 IU/ml) [10]. In atopic individuals
levels of IgE are elevated, in particular levels of IgE specific to the
allergen(s) to which the subject is allergic.
During the initial exposure(s) antigen is processed and presented by
antigen-presenting cells (APC's). APC's present the processed anti¬
gen to CD4+T-Helper2 (Th2) cells which release cytokines, principally
interleukins 4 and 13 (IL4 and IL13). (CD4+ indicates that the cell
expresses the CD4 cell-surface marker.) These cytokines stimulate B
cell proliferation resulting in the production of large amounts of IgE
specific to the antigen. The resulting IgE binds to mast cell IgE recep¬
tor FC£RI. On subsequent exposure the antigen combines with these
IgE on the FC£RI receptors on mast cells stimulating degranulation of
the cell. On degranulation the mast cell releases histamine and other
cytokines which trigger the inflammatory response.
Following antibody binding to antigen, the resulting combination is
then capable of triggering membrane receptors on mast cells. This
results in the release of mediators including histamine, leukotrienes,
prostaglandins, bradykinins and eosinophil chemotactic factors. The
antibodies involved are typically of the IgE and IgG classes.
Type IV (Hyper-sensitivity) Reactions - Cell-mediated immune
reaction
Type IV Reactions are known as cell-mediated responses or delayed
hyper-sensitivity. While Type I reactions occur very rapidly following
25





Figure 1.3: Mechanism of the Type IV (delayed hyper-sensitivity) reaction.
antigen exposure Type IV reactions can take up to 72 hours to ap¬
pear [10]. Delayed hyper-sensitivity reactions include the skin reac¬
tions resulting from intra-dermal injection of allergen. The interaction
between the thymus-derived lymphocytes (T-cells) and the allergen to
which they are specific results in the release of lymphokines, some of
which are cytotoxic to specific target cells (see Figure 1.3).
The sensitisation process in humans can take 10-14 days [10]. Langer-
hans cells in the epidermis internalise hapten-protein conjugates and
migrate to the local lymph node the via afferent lymphatics. Here they
present antigen in conjunction with interferon-7 (IFN-7) and tumour
necrosis factor-/! (TNF — /3) [19]. The stimulation of IFN-7 is typical of
a THeiperi (T//j) cell response and is characteristic of skin sensitisation
[20, 17]. Indeed IFN-7 antagonizes the IgE production associated with















Figure 1.4: Asthma can be influenced by a number of factors.
Occupational Asthma
Occupational Asthma (OA) is asthma caused by sensitisation of the
respiratory tract to workplace chemicals. OA is one of the two forms of
workplace asthma, the other being work-aggravated asthma, in which
pre-existing asthma is made worse by exposure to triggers in the work¬
place. Indeed any case of asthma could be influenced in a number of
ways (see Figure 1.4) and consequently there may be difficulty in diag¬
nosing OA as distinct from asthma caused outwith the workplace.
OA is more readily defined by its symptoms and underlying patho¬
physiology than by its immunology. A wide variety of symptoms such
as cough, chest tightness, wheeze and nasal symptoms may accom¬
pany sensitisation. The factors underlying the main symptoms are
reversible broncho-constriction and excess mucus production. There
is marked variation in symptom presentation. The temporal pattern
of the disease also varies, some cases showing an immediate onset of
symptoms following exposure, whereas in others the symptoms occur
several hours later1 . This variation is seen both between different
1When symptoms do occur several hours after the exposure this can make diag¬
nosing occupational asthma and identifying the responsible agent extremely difficult.
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chemical causes and between different patients sensitised to the same
chemical. The term OA has therefore been said to cover a spectrum of
respiratory disorders [21].
The diagnosis of asthma is performed on the basis of observed symp¬
toms and measurements of lung function. The clinical diagnosis of
asthma is often arrived at by these methods without any identifica¬
tion of the causative agent. Asthma is generally diagnosed as intrinsic
or extrinsic. One of the simplest diagnostic measures is peak expira¬
tory flow rate (PEFR) monitoring. This is simply the maximum rate
a person can expel air from his lungs. It is measured by a peak flow
meter. A more informative diagnostic measure is the forced expiratory
volume in one second (FEVi) which is measure using a spirometer. It
is often desirable to identify whether a reaction is antibody-mediated.
Various methods exist for measuring both non-specific (total) and spe¬
cific serum antibody levels. Assays of specific antibody concentrations
(using for example ELISA techniques [22]) are frequently used because
they are readily available through diagnostic laboratories.
There is a considerable variety of chemicals that cause OA (see p30) so
there may also be problems identifying the causal agent in an environ¬
ment containing mixtures of chemicals. Indeed the gold standard1 di¬
agnosis ofOA to particular chemical can only be achieved by blind chal¬
lenge inhalation with pure compound whilst having controls to elimi¬
nate airway hyper-sensitivity as a cause. Such tests are not trivial,
require specialist equipment and should always be carried out within
a hospital. Some studies also include a challenge of a non-sensitised
control asthmatic exhibiting similar pre-test airways reactivity to the
patient studied [23].
Asthmatic responses may be immediate, delayed or dual. The imme¬
diate response, which may be seen in isolation as in Figure 1.5, is be¬
lieved to be due to a narrowing of the airways by the contraction of the
lrThe term given to describe the best available diagnostic test.
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Time since initial challenge
Figure 1.5: Change in FEV] For Early, Late and Dual Asthmatic Responses.
Schematic Representation of change in FEVi for early, late and dual asth¬
matic responses. (After Cartier and Malo, 1993 [25].)
smooth muscle walls in response mainly to released histamine from
mast cells. It is usually indicative of a Type I immune reaction (see
p24). The response occurs quickly, in some cases in seconds, in others
up to 15 minutes after challenge. Since the early response is primarily
due to smooth muscle contraction it responds well to recovery treat¬
ment using /5-adrenergic drugs such as salbutamol [24].
A dual response type (see Figure 1.5) is commonly seen with classi¬
cal Type I (IgE-dependent, atopy-related, see p24) immediate hyper¬
sensitivity asthma response. An initial fall in lung function (as mea¬
surable by FEVi) is observed within minutes of challenge. This is fol¬
lowed by an improvement of FEV\ though not necessarily a return to
pre-challenge value. Several hours later a second fall in FEV\ is ob¬
served. The cause of the first fall in FEVi is usually the constriction of
the circular smooth muscle of the bronchi walls. The late drop in FEVi
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is typically the result of an inflammatory response resulting in mucus
plugging of the airways.
A delayed response (see Figure 1.5) typically occurs several hours after
exposure to the causative compound. This must often preclude early di¬
agnosis of OA because symptoms occur after the subject returns home
from work thus the correct association between the symptoms and the
chemical exposure is not made. The delayed response type alone is
rarely described in non-OA but is seen in cases of asthma due to alde¬
hydes, amines, acrylates, anhydrides and isocyanates. A delayed type
response may be indicative of a Type IV immune response (see p25)
however it may also indicate a transport latency between chemical
challenge and the chemical reaching its site of action. Interestingly,
Durham et al. [26] notes that
... increases in airway responsiveness precede the late asth¬
matic response, occur independently of changes in airway
caliber, and correlate with the magnitude of the subsequent
late response.
Consequently the delayed response may represent the latency of trans¬
port and triggering of an inflammatory response.
Although Figure 1.5 indicates typical temporal profiles ofFEVi each in¬
dividual case is different. Occasionally unusual response profiles may
be noted such as early-late, progressive, square-waved or prolonged-
immediate [25].
Classes ofLowMolecularWeight Occupational Asth-
magens
A comprehensive classification of occupational asthmagens may include
mammal-derived antigens, insects, flour, tea, wood dusts, vegetable
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gums, laboratory and commercial enzymes, diisocyanates, anhydrides,
aliphatic amines, ethanolamines, heterocyclic amines, aromatic amines,
fluxes, metals, drugs, synthetic materials and a selection of other chem¬
icals. This diversity of chemical asthmagens produces a great hetero¬
geneity of symptoms, such that OA has been described as a spectrum of
disorders [21]. The LMW organic asthmagens can be classed as follows:
Isocyanates
Isocyanates are esters of isocyanic acid (H-N=C=0). Polyfunctional iso¬
cyanates are used in the manufacture of polymeric foams, fibres, coat¬
ing and solid elastomers because they react readily with many func¬
tional groups with a limited amount of undesirable by-product forma¬
tion. The normal reaction of isocyanates involves the addition of an
'active' hydrogen, that is, one replaceable by sodium (Figure 1.8).
Isocyanates find a wide variety of applications from use in spray paints
to the manufacture of mechanical goods, industrial tyres, coated fab¬
rics, shoe products, wire and cable. They are extremely reactive chem¬
icals which have several other toxic effects in addition to being sen-
sitisers. Isocyanates are the most commonly cited and probably the
most potent cause of OA, accounting for in excess of 20% of all cases
of OA reported in the U.K. [27]. One recorded OA fatality was due to
exposure to the exposure of a sensitised worker to paint containing just
0.15% toluene di-isocyanate (TDI, Figure 1.6) [28], It is worth noting
that TDI generally comes as a mix of the 2,4- and 2,6- isomers in a ratio
of about 4:1 [29].
Several other di-isocyanates have been described as causing OA includ¬
ing hexamethylene di-isocyanate (HDI, Figure 1.7) [30, 31], isophorone
di-isocyanate [32], diphenylmethane di-isocyanate (MDI) [33], 1,5-naphthalene
di-isocyanate (NDI) [34]. Respiratory symptoms have been observed in
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Figure 1.7: Hexamethylene di-isocyanate.
GulfWar veterans due to exposure to TDI present in the chemical agent
resistant coatings used to paint military vehicles [35].
It is notable that all the reported causes of isocyanate asthma are due
to di- or poly-isocyanates. This may reflect the more widespread use
of and therefore exposure to these compounds compared with mono-
isocyanates (for reasons detailed below) but may also be a reflection
of a fundamental requirement for bi- or poly-functionality in the im-
munochemistry of isocyanate-induced asthma. However until a de¬
tailed study ofworkers exposed to mono-isocyanates is undertaken this
will remain just a hypothesis.
It is possible that some individuals are more prone to developing asthma
to isocyanates. Savolainen [36] states that c^-anti-trypsin carriers may
be at a greater risk of developing di-isocyanate asthma. The study was
based on only a small number of subjects so this result remains to be
confirmed.
Asthma due di-isocyanates can persist despite negligible workplace ex¬
posure [37] and continued exposure leads to worsening symptoms [38].
The symptoms that accompany di-isocyanate respiratory sensitisation












Figure 1.8: Isocyanates react by an addition mechanism.
Acid Anhydrides
Acid anhydrides are formed when two carboxyl groups react in such a
way that a water molecule is released. They are named after their par¬
ent acid. Acid anhydrides are used as curing agents in epoxy resins [40]
Venables describes in detail the uses and toxicity of acid anhydrides
[40]. Amongst the compounds she cites as capable of causing OA are
phthalic anhydride [41, 40, 42] (see Figure 1.9), tetrachlorophthalic an¬
hydride [43, 44, 45, 40, 46], trimellitic anhydride [42, 47, 40, 48, 40, 49],
maleic anhydride [50], and pyromellitic di-anhydride [40]. Methylhex-
ahydrophthalic anhydride [51], hexahydrophthalic anhydride [48, 47,
40, 52], himic anhydride [49] and methyltetrahydrophthalic anhydride
[53, 54, 55] have also been reported to cause respiratory sensitisation.
Acid anhydrides are amongst the most common chemical causes of OA
[27]. They have a variety of adverse effects [40, 52]. At least one death
is reported which may have been in part due to acid anhydride-related
asthma [45].
Although acid anhydrides can and do have irritant effects they are be¬
lieved to cause asthma by acting as haptens, reacting with endogenous
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protein and eliciting a Type I (IgE-mediated) hyper-sensitivity reac¬
tion [43, 56, 44]. There is evidence that the IgE antibodies character¬
istic of sensitisation may persist for several years after exposure [45].
Enzyme-linked immuno assays can be effective in identifying work¬
ers sensitised to anhydrides [42]. A hapten density in a range 10-25
mol/mol serum albumen appears to be optimal for allergic reactivity
[57] of acid anhydrides. Other affects noted from anhydrides include
haemorrhagic rhinitis, reported due to to exposure to hexahydroph-
thalic anhydride[52],
The Tree Acid Resins, Abietic and Plicatic Acid
Abietic and plicatic acids are found in colophony (rosin) from pine trees
and from cedar respectively. They are known asthmagens. There may
be other asthmagens present in wood extracts but none are as well
characterized as these two chemicals.
Colophony is a natural substance obtained from pine trees [58]. It has
a complex chemical composition of which approximately 90% consists
of di-terpene resin acids. Colophony is used in soldering fluxes to re¬
move surface corrosion (oxides, sulphides or chlorides) [58], The hot
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solder then destroys the flux thus allowing a good contact with the un¬
derlying metal. Most cases of OA due to colophony arise from its use
as a soldering flux but Burge em et al. [59] report a case in a man who
had been working with a bitumen mixture containing colophony. In a
respiratory challenge test he suffered a dual reaction to colophony at
room temperature.
Plicatic acid is believed to be the constituent of both eastern white
cedar (Thuja occidentalis)[60] and western red cedar (Thuja plicata)[61,
62] that is responsible for the respiratory sensitisation of workers ex¬
posed in the timber and sawmill industry.
Reactive Dyes
Reactive dyes are another potent class of sensitiser. Imperial Chemical
Industries first marketed a reactive dye for cotton in 1956 and since
then many more reactive dyes have become available. The popular¬
ity of reactive dyes stems from the availability of bright colours and
the permanence with which they dye textiles. Reactive dyes covalently
attach to hydroxyl and amino groups on the cloth. This is facilitated
by reactive groups such as heterocyclic aromatic halogens or reactive
groups on aliphatic side chains. A further important feature required
for efficient dying is that there must be hydrophilic groups ifwater is to
be used as the dying solvent. The dye colour is due to a light absorbing
system, usually an azo adjacent to aromatic rings.
OA due to reactive dyes typically involves a Type I immune reaction
and invariably, when sort, increased levels of IgE can be demonstrated.
In several cases of OA to reactive dyes, IgE has been demonstrated
[63, 64, 65, 66], Romano et al. describe a case of immediate (there¬
fore probably type 1 immune response) in a worker exposed to the
bromo-acrylic dye, Lanasol Yellow 4G [67]. Noferi describes five cases
of asthma due to the soluble azo dye Direct Black [68]. These reports in
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conjunction with animal studies strongly suggest that OA due to reac¬
tive dyes is a classic type 1 immunological response. This is supported
by the observation that the asthmatic response is immediate following
a respiratory challenge [63]. There is also evidence that reactive dye
induced OAmay occur with an absence of non-specific bronchial hyper¬
reactivity. Reactive dye asthma has been implicated in an OA fatality
[69],
Some non-reactive dyes and colouring agents known to cause asthma
include methyl blue (a component of ECG ink) [70, 71] and carmine (a
natural red dye and food colouring agent) [72, 73],
Aldehydes
Formaldehyde and glutaraldehyde are amongst most commonly used
LMW chemicals reported to cause asthma. Formaldehyde is widely
used in pathology to preserve and fix specimens. It has powerful dis¬
infectant properties. It is used in industry in the formation of urea-
formaldehyde thermosetting resins [74], Similarly, glutaraldehyde is
used as a disinfectant (particularly in disinfecting surgical equipment
[75, 76]) and is also used industrially for tanning leather [74],
The case for formaldehyde being a respiratory sensitiser is controver¬
sial [77]. A study amongst medical students (exposed during anatomy
classes to formalin-preserved cadavers) found little evidence to suggest
respiratory sensitisation was occurring [78]. It should be noted how¬
ever that formaldehyde has been shown to produce asthmatic symp¬
toms when a 'sensitised' worker was exposed to formaldehyde in a
challenge test [79]. Burge et al. (1985) [80] noted a significant asth¬
matic reaction in a patient challenged with 1% formaldehyde solution.
The same patient experienced rhinitis and watery eyes 10 hours af¬
ter exposure to 0.1% formaldehyde. Clearly, formaldehyde sensitisa¬
tion does occur in some individuals. From a mechanistic standpoint
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Figure 1.10: Hexachlorophene - a germicidal additive to soaps.
formaldehyde does not appear to elicit the standard IgE type I immuno¬
logical typical of other respiratory sensitisers [77]. This may indicate
that formaldehyde asthma is due to an irritant effect (as suggested by
Hilton et al., 1996) [77] or an as yet poorly understood immunological
process.
Other Cleaning and Sterilising Agents
Burge and Richardson report a case of a pharmacist sensitized to the
cleaning agent lauryl dimethyl benzyl ammonium [81]1. Lauryl dimethyl
benzyl ammonium chloride is one of a class of biocides with general
formula 'alkyl' dimethyl benzyl ammonium chloride. A report by In-
nocenti describes a case of OA due to benzalkonium chloride but does
not sufficiently speciate the compound [82]. Chloramine (chloramine-
T) is used as a sterilising agent in industries such as brewing. There
have been several reports of it causing OA [83, 84, 85]. Chlorhexi-
dine, a known skin sensitizer, caused asthma in a nursing auxiliary
exposed to the compound in a chlorhexidine and alcohol spray [86].
The topical antiseptic/disinfectant hexachlorophene [87] which is used
as a germicidal additive in soaps has also caused asthma in a nurse
(see Figure 1.10). Finally, a detergent additive, sodium iso-nonanoyl
oxybenzene sulphonate [88] caused asthma in a laboratory technician.
1The same paper also mentions that the pharmacist had his first asthma attack





Ethanolamines are widely used in the production of soaps, detergents,
spray paints, cosmetic formulations and shampoos due to their emulsi¬
fying properties. They are also used as lubricant additives, plasticizers
and corrosion inhibitors [89]. Ethanolamines are also found in solder¬
ing fluxes [90].
There have been a number of reported cases ofOA due to ethanolamines:
ethanolamine [91, 89], aminoethyl-ethanolamine [92, 90] (see Figure
1.11), dimethyl ethanolamine [23], triethanolamine [89] and 2-diethyl-
ethanolamine [93]. 3-(Dimethylamino)propylamine, a volatile compo¬
nent of an epoxy resin used in ski manufacture, has also been re¬
ported to cause symptoms not incompatible with a diagnosis of OA
[94]. Interestingly there is an absence of reported cases of asthma due
to ethanolamines in cosmetics manufacture. This may indicate that
the differences in method of ethanolamine employment are critical to
health outcomes. One such difference may be the temperature at which
the ethanolamines are used.
Other Amines Known to Cause Asthma
These include ethylene diamine [95, 96, 91], piperazine / piperazine
dihydrochloride [91, 97, 98], hexamethylene tetramine [91], N-methyl







Figure 1.12: Methyl-methacrylate is found in super-glues.
Acrylates Known or Suspected to Cause Asthma
Acrylates and cyanoacrylates known to cause OA include methyl-methacrylate
[102, 103] (see Figure 1.12), methyl-cyanoacrylate [104, 103, 105] and
ethyl-cyanoacrylate [103]. Nakazawa describes a case of (probably IgE-
mediated) OA due to "alkyf'-cyanoacrylate in super-glue but does not
specify which alkyl group was present [106], Chan et al. report a case
ofasthma due to "cyanoacrylate" but again they do not specify the exact
chemical [107]1.
Methylmethacrylate is used as bone cement in surgical operations [105],
cyanoacrylates are commonly found in super-glues [106], It has been
noted that ambient air concentrations of acrylates are dependent upon
humidity. In high humidity the water vapours "mop" up cyanoacry¬
late vapours thereby neutralising the hazard [103]. Chan et al. note
a low incidence of cyanoacrylate-induced asthma in Singapore is prob¬
ably due to the high humidity there [107]. Savonius et al. [108] cite
a number of suspected cases (several requiring further confirmation).
These include asthma apparently due to acrylic acid, methacrylate,
isobutyl-methacrylate, trihydroxy-methyl-propyl-triacrylate, hydroxy-
propyl-acrylate and methyl-cyanoacrylate.
1It is unfortunate that so many case reports, despite performing challenge tests,
fail to identify the exact chemical responsible.
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Figure 1.13: Tetrachloroisophthalonitrile - one case of asthma reported due
to this fungicide.
Fungicides and Insecticides
Fungicides and insecticides have on rare occasions been reported to
cause OA. The fungicides tetrachloro-isophthalonitrile [109] (see Fig¬
ure 1.13) and captafol (Difolatan) [110]; and the insecticides phosdrin
(also known as mevinphos) [111], fenthion [112] and dichlorvos [112].
Drug and Drug Intermediates
A large number drugs and drug intermediates have been linked to
asthma both following administration therapeutically and by inhala¬
tion by workers handling these chemicals. Amongst the cases of OA
the subjects have usually been workers exposed to large quantities of
the drug during its manufacture. On occasions allergic reactions have
been noted in medical personnel charged with the task of administer¬
ing these drugs to patients.
The most common pharmaceutical products linked with OA are /i-lactam
antibiotics. These include benzyl penicillin [113], 6-amino penicillamic
acid [113], 7-amino cephalosporanic acid [114], ampicillin [113], cephal¬







Figure 1.14: Enflurane is an inhalation anaesthetic.
only antibiotics to be implicated, cases of OA due to the macrolide an¬
tibiotic spiramycin [116, 117, 118] and tetracycline [119] have also been
reported.
In addition several other compounds which are either medicinal agents
or intermediate chemicals in the manufacture of medicines have been
reported to cause asthma. The include the anti-hypertensive drug
methyl DOPA [120], the anti-ulcerative drug cimetidine [121], the opi¬
ate morphine [122], MM22383 [123], dioctyl phthalate [124], phenyl-
glycine acid chloride [125], hydralazine (an anti-hypertensive drug)
[126], sulfathiazole (used in the manufacture of the bacteriostatic sul-
phanilimide) [127], isonicotinic acid hydrazide (an anti-tuberculosis
drug also known as isoniazid) [128], penicillamine [129] and glycyl
compound [130]. There has also been a report ofchanges ofself-recorded
air flow measurements in an anaesthetist repeatedly exposed to enflu¬
rane1 [131]. Finally there is a report that salbutamol [132] and another
drug used in the treatment of asthma, aminophylline [133] have been
reported to cause asthma.
Other Chemicals
Other chemicals reported to cause asthma include styrene (used to
make polystyrene plastics) [102, 134, 135, 136], A-3-carene (found in
rubber gloves) [137], azobisformamide (a blowing agent also known as
azodicarbonamide) [138, 139], Pauli's reagent [140], tetrazene (used in
detonator manufacture) [141], furfuryl alcohol (in a furan-based binder
1The paper descibing asthma due to enflurane was missed and so this compound
was not included in the study until it was entered as a validation compound.
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system) [142], amprolium hydrochloride (a poultry food additive) [143],
ethylene oxide [144, 145] and possibly hydroquinone [146] and methio¬
nine [146], The majority of these (styrene excepted) have only been
documented as causing asthma in one or two cases.
Occupational Contact Dermatitis
Occupational contact dermatitis (OCD) is the skin sensitisation as a re¬
sult of dermal contactwith workplace chemical agents. Many hundreds
of chemicals have been reported to cause cause OCD, though a propor¬
tion of these will cause irritant rather than allergic dermatitis. The
symptoms of dermatitis may be localized to the point of contact or in
severe cases may spread to include other areas of skin. The area may
show erythema (reddening), be pruritic (itchy), have maculo-papules
(small raised, circumscribed lumps of infiltrating inflammatory cells),
be inflamed and in severe cases the stratum corneum may be cracked.
Irritant dermatitis is due to acute effects ofthe chemical on the skin. Ir¬
ritant dermatitis does not imply any sensitisation and is not of an aller¬
gic nature. Allergic contact dermatitis implies that sensitisation does
occur and that re-exposure will evoke a more pronounced response. It
is possible for a chemical to be a cause of both irritant and an allergic
contact dermatitis. It is also possible that chemicals with the potential
to sensitize only do so in the presence of a secondary irritant substance.
Such a secondary adjuvant is used in immunological studies of allergy
to promote and accelerate the sensitisation process. Mechanical com¬
promise of the skin or constant 'wet work' can also facilitate the onset
of contact dermatitis to chemical agents. Dermatitis can also be ag¬
gravated by the presence of pathogens such as Staphylococcus aureus
[147],
The two phases to the presentation of allergic contact sensitisation are
induction and elicitation. Induction is the phase during which sensi-
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tisation occurs. Elicitation is the subsequent eczematous reaction to
re-exposure to the substance.
A wide variety of occupations present an occupational contact dermati¬
tis hazard. In addition to the manufacturing industries in which chem¬
icals are made and used personnel in a number of service industries
are also affected. These include caterers, garage mechanic and hair¬
dressers.
It is now becoming accepted that skin and respiratory sensitisation oc¬
cur by different immunological mechanisms [56, 19, 148, 17, 20, 149],
However there are a number of chemicals (perhaps more than 20) that
have been reported as causing both asthma and dermatitis. These
include the aldehydes (glutaraldehyde [150, 151, 152]) and some iso-
cyanates (for example hexamethylene di-isocyanate [153, 154], toluene
di-isocyanate [153] and diphenylmethane di-isocyanate [155,156,153]).
Interestingly, no acid anhydrides appear to have been reported to cause
skin sensitisation however some of the derivative acids such as hexahy-
drophthalic acid have [157],
1.4 Structure-Activity Relationship Studies
Overview
Structure-activity relationships (SAR's) are associations between a chem¬
ical's structure and its activity, whether the activity is a physical, chem¬
ical or biological property. To perform a SAR study one needs to be able
to represent structure and activity in a manner in which qualitative




A commonly held visualisation of chemical structure (at least amongst
non-chemists) is that of the classical Lewis structure 'graph' two-dimen¬
sional diagrams. Lewis theory assumed that atoms bond by sharing
electrons thus completing their shells without ionisation. Graph repre¬
sentation is so commonplace that there is a tendency for non-chemists
to think ofmolecules solely in terms of such structural representations.
This empirically drawn up representation of chemical structure is lim¬
ited. The structure of benzene must be represented by at least two res¬
onance structures using this format even though measurements sug¬
gest all the carbon-carbon bond lengths in benzene are equal. In reality
chemical structure is far more complex. The exact forces that hold a col¬
lection of atoms within the relatively stable state seen in molecules are
not well understood. These forces mean that molecules are dynamic.
Chemical structures are not rigid.
Chemical structures can be represented in a number of increasingly
descriptive ways. The methods of description have improved as larger,
more complex chemicals have been described. Although chemicals can
be described in empirical formula, such a description is too simplistic to
use unless the molecules are very small. Chemical descriptions must
be sufficient at least to describe the topological relationship between
the atoms of a molecule. The topology of a molecule is the description
of which atoms are connected to which other atoms. In addition it is
sometimes important to specify the topography of a molecule. Topogra¬
phy refers to the positional co-ordinates in three dimensional space of
each atom in a molecule. Two chemical structures may be topologically
identical but topographically different (because for example they are
stereo-isomers). It may also be necessary to a study that no two differ¬
ent chemicals have the same description. The definition of 'different'
may depend on the context of the chemical study. In this study topo¬
logically equivalent compounds are considered identical even if they
44
beta-lactam ring











Figure 1.15: Chemicals can be described by their substructure fragment con¬
tent.
differed stereo-chemically.
The storage and retrieval of chemical structure is well reviewed else¬
where [158, 2, 159]. Storage is a compromise between accurate rep¬
resentation and fast retrieval by querying. Accurate representation
involves having tables of all connections of all atoms. One of the many
accepted chemical representation formats is the 'molfile' format [159]
from MDL1 and it is this format that has been used in this study to
store structure data. There is a complication with mobiles in that they
do not necessarily include hydrogens [159]. The hydrogens are consid¬
ered implicit (although they may sometimes be explicitly represented).
The approach used to describe structure in this work is similar to that
described as atom/bond-centred by Bawden [158], Briefly, molecules
are described by a string of numbers representing the number of oc¬
currences of particular substructure-fragments. These fragments may





The fundamental assumption that underlies most attempts to predict
properties from chemical structural data is that structurally similar
molecules will exhibit similar properties [2]. Indeed it has been argued
that properties ofchemicals are ultimately a function of their structure:
The structural formula of an organic compound, in princi¬
ple, contains coded within it all the information which pre¬
determines the chemical, biological and physical properties
of that compound. [160]
Essentially, structure activity relationships are made by formingmath¬
ematical descriptions of the relationship between structure1 and activ¬
ity. Given such a mathematical description one can apply the same
relationship to a chemical whose structure is known but whose activity
is not. Hence mathematical description gives a prediction of activity
based on prior observation.
The accuracy of prediction is based on the quality of the mathemati¬
cal description of the relationship between structure and activity, both
in terms of the validity of the mathematical expression and the reli¬
ability of the data. If chemical structures or activities are wrong the
model will fail. Equally, if the mathematical expression does not at¬
tempt to exclude coincidental structure-activity relationships then the
model will only be relevant to the original learning set of structures
and activities. In short, each constant and coefficient in a predictive
expression must be justified in terms of statistical validity.
The type of prediction produced by a predictive model may take one of
several forms. Predictions can be true or false (qualitative); categorical
(qualitative); or quantitative. The prediction may take the form of a
xOr a property clearly derived from the structure, such as molecular mass
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probability of an outcome. So, for example, if predicting the weather a
model might predict whether precipitation will occur; whether it will
be rain, hail, sleet or snow; what the probability of rain is; or how many
inches will fall.
This study of chemical sensitizing potential forms a prediction that can
be taken as a binary value or as a probability. In essence, it addresses
the question "is this compound a hazard" and the resulting prediction
can either be taken as yes or no, or perhaps more usefully the probabil¬
ity that it is a hazard. It is not a measure ofhow hazardous a compound
is.
Measuring Predictive Power
It is important to know how good a model is at prediction. Given that
there are imperfections in every model it is useful to quantify how good
a model is. The residuals - the difference between observed and pre¬
dicted values - provide a means of doing this. With binary or classi¬
fication prediction (in which the prediction will assign to a particular
category) there can be measures of specificity and sensitivity (see p77).
Sensitivity describes how well a model correctly assigns those values
which belong in a category. Specificity describes how well the model ex¬
cludes values from a category in which they do not belong. It is worth
noting that sensitivity and specificity for the same predictive test are
reciprocally related.
Validating Predictive Models
If a predictive model is to be of use it should be validated . A measure
of how frequently it produces the correct result is needed. In order to
achieve this a validation data set that is independent of the learning
data set is required. A model than can then be tested on a previously
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unseen data set to ascertain whether its predictive performance is of
general use rather than merely specific to its learning data set. It is
measurements such as predictive power, sensitivity and specificity cal¬
culated for a validation data set which best indicate whether a model
is 'good'.
1.5 Aims
The aims of this thesis can be described in three parts: firstly, the
collection of data; secondly, the use of that data to describe (and pre¬
dict) occupational chemical sensitizing hazard using chemical struc¬
ture; and thirdly the use of that relationship to stimulate novel mecha¬
nistic hypotheses. Throughout, the emphasis will be placed on finding






The study design consisted of three major stages: data collection; data
analysis; and data validation. The first stage, data collection, involved
the compilation of a database of control and asthmagenic chemicals.
The second stage, the data analysis, involved the creation ofa structure-
activity relationship for these chemicals in order to model and predict
their respiratory sensitizing ability. The third stage, the data valida¬
tion, involved the testing of the predictive models resulting from the
second stage with a previously unseen (validation) set of controls and
asthmagens.
The study was not however restricted to the difference between asth¬
magens and control chemicals. From the outset, an additional set of
chemicals known to cause skin sensitisation was to be compiled and
this too compared with the set of asthmagens. It should stated how¬
ever that a comparison between the skin sensitizers and the controls




Searches of the medical literature up to the end ofDecember 1994 were
carried out using the MedLine Database1. Published cases of chemi¬
cally induced OA and allergic contact dermatitis were assessed for in¬
clusion in this study as the 'active' compounds. The disease had to be
occupational in origin. A further restriction was to limit the papers to
those describing human results using the MedLine option limit to hu¬
man (for example, see option 10, Table 2.3). 'Control' compounds were
selected from compounds in use which are known to be hazardous. The
chemical identity (speciation) of all substances used had to be clear (in
terms of a definitive chemical structure) . Organometallic complexes
with transition metals where excluded but organic salts formed with
other metal ions were accepted. There was no restriction on the allow¬
able elements in the compound, however for the purposes of this study
'organic' was defined as 'carbon-containing'. (Therefore compounds that
did not contain at least one carbon were rejected.) All compounds se¬
lected were of molecular mass less than 1000.
Asthmagens
Since the use of the MedLine 'keyword' system is not sensitive, merely
specific, several textword based searches were performed in which words
synonymous with the general topics of occupational disease, sensiti-
sation and respiratory disease were used (see Table 2.1) . The ini¬
tial asthmagen searches preceded the search for contact sensitizers
but the later searches benefited from the lessons learnt from the skin
search validation (see p55). All search results were added to a reference
1This is provided by CHEST Ovid Biomedical Service. See





industry respiratory symptoms allergic
manufacture pulmonary oedema hyper-sensitivity
manufacturing anaphylactic shock
Table 2.1: Asthma keywords used in multiple MedLine searches.
database (the package Reference Manager was used). The reference
database software readily enabled checks to ensure papers were only
entered once. Approximately 2000 references resulted which were re¬
viewed by title and abstract and were potentially relevant by apprais¬
ing the full paper to identify reports of respiratory sensitizers.
The references identifying respiratory sensitizers were studied in depth
and the potentially relevant available epidemiological data tabulated1.
Data obtained included reported prevalence, type of response, evidence
of IgE involvement, latency and persistence of disease. These data
were tabulated by categorising (See Table 2.2). Many of the fields re¬
mained blank or reported 'no data available' to indicate the fact that
such data were sought. A record of the relevant references and any
additional miscellaneous notes (e.g. for glutaraldehyde the field states
'Highly toxic, corrosive, protein cross-linking agent') were also made.
Active chemicals were defined as substances for which a physician had
in a peer reviewed report clearly diagnosed OA arising following a la¬
tent period of exposure.
1This aspect of the study could be viewed as prospective since during the record¬
ing stage it was not clear which epidemiological data would prove useful. As a conse¬




Table 2.2: Format of the clinical data coding protocol
Category Coding Options
Absolute prevalence 0. No known cases
1. A single case report
2.Up to 3 cases
3. Up to 10 cases
4. Up to 33 cases
5. Up to 100 cases
6. Up to 333 cases
7. More than 333 cases
Percentage prevalence 0. No data available
1. Less than 1%.
2. In the range 2-4%
3. In the range 5-9%
4. In the range 10-24%
5. In the range 25-49%
6. In the range 50-74%
7. In the range 75-100%
Sensitising Concentration 0. No data available
1. Less than 0.0001 //Moles/1
2. Less than 0.001 //Moles/1
3. Less than 0.01 //Moles/1
4. Less than 0.1 //Moles/1
5. Less than 1. //Moles/1
6. Less than 10 //Moles/1
7. Less than 100 //Moles/1
8. Less than 1000 //Moles/1
9. More than 1000 //Moles/1




3. Immediate or late
4. Dual
5. Immediate or dual
6. Late or dual
7. Early, late or dual
IgE testing 0. No data available
1. No evidence found.
2. Elevated total IgE levels
3. Specific IgE found
Basis for diagnosis 0. No data available.
1. Workplace observation
2. Respiratory challenge.
Percentage atopic 0. No data available
1. Less than 1%
2. Less than 5%
3. Less than 10%
4. Less than 25%
5. Less than 50%
6. Less than 75%
7. More than 75%
Latency (median) 0. No data available
1. Up to 1 month
2. Up to 6 months
3. Up to 1 year
4. Up to 2 years
5. Up to 3 years
6. Up to 5 years
7. Up to 10 years
53
Controls
Similar chemical criteria were employed for the inclusion of control
compounds. The control chemicals were selected from the Tables 1
and 2 of the Health & Safety Executives EH40/94 Occupational Expo¬
sure Limits 1994 document which detail occupational exposure indices
[161]. All the listed organic compounds (excepting those which were al¬
ready included in the study as active) and for which a structure could
be identified were used. If a limit was set for all structural isomers of
a compound, then all those isomers were included.
Contact Allergens
The criteria for selection of the occupational skin sensitizers closely
mirrored those for the asthmagens and the controls. The storage of
the compounds was done using the IsisBase package1. The significant
difference between the collection of the asthmagens and the skin sensi¬
tizers was that for the latter an upper limit of 200 compounds was set.
Whilst considerably in excess of 200 skin sensitizers are known [162],
not all of these are cited as occupational skin sensitizers. The spe¬
cific criteria needed for a compound to be included as a skin sensitizer
were: the compound contained carbon; the molecular weight was less
than 1000; the compound caused allergic contact dermatitis; and that
the compound caused the disease through occupational use. A system¬
atic search through MedLine was performed using the MedLine search
criteria detailed in Table 2.3. The results of this search were then ex¬
amined in order to identify possible candidate chemicals by evaluating
the title and abstracts. Compounds for which there was doubt about
whether they fulfilled the chemical structure criteria were at this stage
:A chemical structure database available form MDL Inc., see
http: / /www.mdli . co.uk/ for company details.
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6. 2 or 3 or 4 or 5
7. allergic, tw and 4
8. 1 and 6
9. 7 or 8
10. limit 9 to human
Table 2.3: Initial MedLine search strings for the identification of skin sensi¬
tizers.
still included. For the years 1966-1975 additional textwords (to recog¬
nise allergic contact dermatitis) had to be used as MedLine's subject
headings were not extensively used over that period (i.e., the first op¬
tion in Table 2.3 was ineffective).
A validation search was then performed using a exhaustive trawl of
one year's publications in perhaps the most authorative journal of der¬
matitis published in English - Contact Dermatitis. The year 1992 was
selected semi-randomly - a fairly recent year was needed because the
local source of Contact Dermatitis did not have the full set of years for
the journal. Using Contact Dermatitis, Volume 26, 1992, all possible
candidate compounds were identified. These were compared with com¬
pounds previously identified from the MedLine search as originating
from Contact Dermatitis, Volume 26, 1992. A number of compounds
not previously identified arose in this validation search indicating the
shortcomings of the original searching terms. Using the data from the
validation search, further search criteria were applied in addition to
those in Table 2.3. These were entered as textwords and are described
in Table 2.4. They fell into three classes - synonyms of occupational,
synonyms of dermatitis and synonyms of allergic. In particular the













Table 2.4: Additional criteria added to the search for skin sensitizers.
Table 2.4).
The effectiveness of the first literature search for contact sensitizers
was barely 20%. Of 28 references considered relevant in Volume 26 of
Contact Dermatitis 1992 only 6 had been found in the initial search
(see Table 2.3). From this it was evident which keywords were missing
from the search (see Table 2.4).
Having identified in excess of 200 potential candidate compounds the
definitive chemical structures were obtained using a number of sources,
principally the Beilstein Crossfire service (then available on trial from
Daresbury Laboratory but now part ofMIDAS). Other sources of struc¬
tures were the Merck index, the Aldrich catalogue and the Chemical
Abstracts. After the exact structure was determined those compounds
which no longer satisfied the study chemical structure criteria were
discarded.
The Validation Chemicals
A validation set of chemicals was prepared by Dr Raymond Agius1.
Control chemicals from later editions of the EH40 Occupational Expo¬
sure Limits documentation were used. Asthmagens were selected from
cases of chemically induced OA published from 1995 onwards. Sus¬
pected asthmagens were kindly made available from those reported to
lDr Raymond Agius, Department of Public Health Sciences, The University of
Edinburgh.
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Controls Asthmagens Skin sensitizers
Learning set > 100 ~100 200
Validation set ? ? N.A.
Table 2.5: Summary of the Expected Content of the Data Sets.
the SWORD1 scheme [27, 163], All the validation chemicals were sys¬
tematically checked to ensure that the structures had not been present
in the learning data sets under different names.
Summary of the Data Sets
The data sets to be used were expected to contain approximately the
number of chemicals described in Table 2.5. There is some overlap of
some of the data sets (see Figure 2.1), indicating that some compounds
were common to both data sets. The relevance of any overlap depended
upon which data sets were being compared (see Figure 2.2). So for the
analysis of the differences between skin and respiratory sensitizers,
the components in the overlap A' of Figure 2.1 were necessarily ex¬
cluded. These compounds (in overlap A', Figure 2.1) could however be
included in the analysis to distinguish between asthmagens and non-
asthmagens, as indeed could the compounds in overlap 'B'. The stated
definitions for asthmagens (see p50) and controls (see p54) are inde¬
pendent of the definition given for skin sensitizers (see p54), hence the
comparison between the two is unaffected by the skin sensitising sta¬
tus of the compounds. Finally, the compounds in overlap 'C' (Figure
2.1) which were controls in the learning set could be 'promoted' to the
set of validation asthmagens (which were selected later).
1Surveillance of Work-related and Occupational Respiratory Disease, a scheme
introduced in 1992 to allow chest physicians to report occupational groups and agents
with a high risk of respiratory disease (including asthma).
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Figure 2.1: Summary of Data Set Overlap.
2.3 Chemical Structure Data
Storing Chemical Structures
Chemical structures were stored as MDL *.mol files [159] (see Figures
2.4 and 2.3) inside the MDL IsisBase package (IsisBase 1.2.1, MDL14,
[159]). The compounds in the database were analysed using a modified
case-control approach [164], The case-control study methodology was
adapted to use chemical entities rather than subjects as the study pop¬
ulation (see pl8). The 'cases' were reported causative agents of OA,
whereas the 'controls' were matched hazardous occupational agents
which were not reported causes of OA. The 'exposures' were the se¬
lected chemical substructure fragments contained within the popula¬
tion.
The chemical structure drawing package IsisDraw1 was used to draw

















Figure 2.2: Overview Showing Which Data Set Pair Comparisons Were
Made.
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Figure 2.3: Methyl-2- cyanoacrylate as represented by the MDL *.mol molfile
in Figure 2.4.
in the structures. The molfile format is a chemical structure connection
table with a header, a counts line, an atom block and a bond block.
The header consists of up to 3 lines: a comment or molecule name line;
a line detailing the type of application which generated the table, the
date and time of its creation; and a further comment or description line
that even if empty must be present.
These lines are followed by the counts line which gives the number of
atoms and bonds (plus several additional flags) in the molecule.
There then follows the atom block, containing the x, y, and z co-ordinates
of the atom and the element symbol for the atom. As this study used
only topological (rather than topographical) structural information the
positional coordinates were not used.
Finally, for the bond block, the first two numbers of each line indicates
the numbers of the respective atoms from the atom list, and the third
number indicates the bond type between these two atoms. (A value of
1 indicates a single bond connection, 2 a double bond and 3 a triple
bond.) The full MDL molfile specification does describe further "flags"
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Figure 2.4: Example of an MDL Molfile.
This figure shows a connection table for methyl-cyanoacrylate (see 2.3) Addi¬
tional redundant flags to lines of the atom and bond blocks have been omitted
for clarity (see 2.5 for the full version).
61
c N ., .. Ar_N xccx category MOLMASS MOLNAME
9 0 . 0 0 0 108.10 3-Methylstyrene
6 4 . 0 4 1 128.09 Hexamethylene_tetramine
Table 2.6: Structure represented by fragment occurrence frequencies.
Large numbers of structures and their property data could be collec¬
tively stored using an identical connection table format in MDL * . sdf
files [159], an ASCII file format (see Figure 2.5) available when using
IsisBase. Chemical and clinical property could also be stored in these
files. The data for each molecule follows the connection table. Separate
molecule entries are demarcated by the $ $ $ $ flag on a line by itself.
Describing Structures: Fragments
Throughout this study the term fragment is used to refer to the type of
chemical structure descriptor used. Fragments were selected from the
represented atom types and known chemical groups observed within
the set of chemical structures studied. The selection of fragments was
partly subjective. The fragments selected tended to be small and fairly
commonly occurring within the dataset of chemicals. Fragments were
not necessarily distinct chemical structures. The resulting tabulated
fragment occurrence frequencies for each of the studied chemical struc¬
tures provided a numerical structure description (see Table 2.6)1.
Two types of fragment were used in this study (see Figure 2.6). The
first may be represented in a standard connection table2 - however it is
not necessarily a distinct structure since unfilled valencies do not imply
hydrogen atoms. (Unfilled valence could be matched to any atom type
xThc fragment content description may be the same for two topologically different
molecules. For example the various isomers of xylene (that is dimethyl benzene) are
topologically distinct but have the same fragment description.
2The 141 Type 1 fragments used may be obtained from the file :





3 . 3204 -3.2958 0.0000 c 0 0 0 0 0 0 0 0 0 0 0 0
4.5115 -4.0083 0.0000 c 0 0 0 0 0 0 0 0 0 0 0 0
5.8027 -3.2958 0.0000 c 0 0 0 0 0 0 0 0 0 0 0 0
4 . 5088 -6.0936 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
5.8027 -2.0417 0.0000 0 0 0 0 0 0 0 0 0 0 0 0 0
7.0522 -3.9333 0.0000 0 0 0 0 0 0 0 0 0 0 0 0 0
8.2934 -3.2958 0.0000 c 0 0 0 0 0 0 0 0 0 0 0 0
4.5124 -4.9917 0.0000 c 0 0 0 0 0 0 0 0 0 0 0 0
1 2 2 0 0 0 0
2 3 1 0 0 0 0
8 4 3 0 0 0 0
3 5 2 0 0 0 0
3 6 1 0 0 0 0
6 7 1 0 0 0 0











Figure 2.5: Format of a single record (for methyl cyanoacrylate) of an
MDL * . sdf file.
Properties of the chemical can easily be read, for example the CAS number
property (CAS#) for this compound is [137-05-3]. The $$$$ line indicates the
end of the record. This example only shows three property fields, in the full
database there were many more. Note: In Figure 2.4 the additional flags in
the atom and bond blocks shown here were omitted.
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in the molecule under investigation.) The second type, (Type 2 Frag¬
ments) are characterised by having rules affecting the degree of vari¬
ability tolerated for a bond or node (atom position) in a skeleton struc¬
ture. These rules are hard coded in a computer program subroutine
specific to that fragment. Twenty eight such subroutines were writ¬
ten (based on information derived from Type 1 fragment analyses)1. In
addition a atom-finding routine was also included that calculated the
number of occurrences of a specified atom (see Appendix B).
Both the Type 1 and the Type 2 fragments were chosen subjectively by
consideration of the possible fragments available in the dataset and by
the requirement that the fragment should occur sufficiently frequently
so as to have the potential to be of statistical significance. Although
Type 1 fragment selection was subjective a degree of method was em¬
ployed to ensure that a moderately systematic approach was
To illustrate the difference between the two techniques it is appropri¬
ate to use an example. Consider the amine chemical group, a group
which is centred around a nitrogen single bonded to at least one car¬
bon. Amines can be 1°, 2° and 3° (depending on whether they have
two, one or no hydrogens attached to the nitrogen respectively). If we
wish to have a single fragment representing all possible amine types,
1°, 2° and 3° we have a problem with Type 1 fragments. We cannot
specify a single connection table which will match 1°, 2° and 3° which
will not also match several fragments which are not amines (see Fig¬
ure 2.7)2. Figure 2.7 does not show an exhaustive list of compounds
which would match the fragments. An additional consideration is the
presence of atoms bonded to the carbon atom - for example an oxygen
1For the definitive description of these fragments refer to the program source code
in the file
[CDROM_DRIVE_LETTER] :\programs\sdf\newfrag.sdf on the CD
2It may seem odd to want to combine the three amine types as in doing so one
loses structural detail however it should be remembered that for a fragment to be
of relevance it must occur frequently in the set of compounds. By combining certain
similar groups, occurrence frequencies are more likely to approach values which will
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Figure 2.6: Two Types of Fragment (Types 1 and 2) Were Used
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double bonded to this carbon would make the group an amide rather
than an amine group. Type 2 fragments overcome this problem be¬
cause one can specify that the atom at a particular node must be of
element A or B but not C. The more flexible rule based criteria of Type
2 fragments can also be applied to bonds - for example one can have
a fragment that matches all occurrences of carbon bonded to nitrogen
irrespective of whether it is by a single, double or triple bond. It may
appear that Type 2 fragments are far better but they do have a major
drawback. Each fragment must be hard coded in a subroutine, which
requires writing and testing.
In contrast Type 1 fragments can easily be added to an *.sdf dictio¬
nary1 of fragment structures merely by drawing them with IsisDraw
and copying them into IsisBase. The tabulating program then reads
a connection table for the fragment and calculates the occurrence fre¬
quency in each chemical structure studied.
The two types of fragments were employed effectively as follows: Type
1 fragments were used to screen a large dictionary of chemical sub¬
structures (up to 130) to identify those which were disproportionately
distributed between the active and control compounds studied; then,
having identified the most relevant Type 1 fragments, these were re¬
fined into Type 2 fragments.
The creation of fragment occurrence tables for compounds was per¬
formed using two computer programs (one for each fragment type) writ¬
ten in the programming language 'C'. This was necessary both to re¬
duce the time required to compile the tables and also to ensure consis¬
tency of fragment matching. In theory the programs should be portable
to any machine with a suitable compiler (although users of MS-DOS /
Windows 3.x may experience difficulties with memory allocation).
1A fragment dictionary is simply a collection of fragments against which matches
could be made.
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Figure 2.7: How fragments match.
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2.4 Data Analysis
The analytical methods used for interpreting the data included: clus¬
tering techniques based on graph theory; adapted odds ratios which in
this text are termed hazard odds ratios (HOR's); and the use of applied
logistic regression modelling. All these methods depend upon the a
priori assumption that structurally similar molecules will exhibit com¬
parable properties [2] consequently each method represents a test of
the null hypothesis (see p!5).
Clustering
Clustering is a technique by which "entities" (in this case chemical
structures) are assigned to groups according to similarity. To achieve
this the entities must be compared by means of "descriptors" (for exam¬
ple in this study chemical substructure fragments are used to describe
the chemicals).
For each chemical studied a point in iV-dimensional space can be as¬
signed. N is the number of descriptors (substructure fragments) used
to describe each compound. So for nth descriptor (fragment), the posi¬
tion along the nth axis is given by the value of that descriptor. In the
case of a substructure fragment, the position along the nth axis equates
to the number of times the fragment has occurred in the compound.
The result is that each compound can be described by a grid reference
like a position on a map, except that there are generally more than 2
dimensions!
The distance between entities (compounds) is a measure of their sim¬
ilarity (or dissimilarity). The distance can be easily calculated using
classical Euclidean geometry: the distance ditj between the two objects
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(i and j) is given by Equation 2.1 where N is the total number of de¬
scriptors and in and jn are values for nth descriptor of entities i and j
respectively [165].
It is possible for the descriptors to take the form ofbinary or continuous
variables. The similarity measures predominantly used in this thesis
uses n continuous variables. Where not explicitly mentioned continu¬
ous variables should be assumed. For some of the clustering analyses
(those based on presence or absence of substructure fragments) the n
variables took a binary form. These latter similarity measures will be
identified as such by explicitly indicating that binary variables were
used.
Three clustering methods are described. The first two - the Ward and
the Jarvis-Patrick methods - are only briefly detailed as the clustering
done using these methods was performed on a preliminary dataset by
Dr. Geoff Downs1. The third method - the Guenoche method - was
also used by Dr Downs on the preliminary dataset and this appeared
to produce the most reliable results. This was in agreement with an
earlier study [166]. Consequently, following discussion with Dr Downs,
the Guenoche method was implemented for further clustering studies.
The Ward Method ofClustering
The Ward Method of Clustering [166] involves identifying all the re¬
ciprocal nearest neighbour pairs (i.e. for pairs x and y, x is y's nearest
neighbour and y is x's nearest neighbour). The method then merges




these pairs into a hybrid pair. It was only used for the preliminary
study by Dr Downs.
The Jarvis-Patrick Method of Clustering
The Jarvis-Patrick Method ofClustering [167, 166] is a non-parametric
technique based on shared nearest neighbours. Two points are as¬
signed to the same cluster if they share a set threshold number of
nearest neighbours. The two points must also contain each other in
that nearest neighbour list. It too was only used for the preliminary
study by Dr Downs.
The Guenoche Method ofClustering
The Guenoche Method of Clustering is an example of divisive hierar¬
chical clustering. It uses a parametric method. It depends upon a table
of the 22V differences between all pairs ofN compounds. The algorithm
is:
1. Calculate the distances between all possible pairs of points.
2. Select the most distant pair of points x and y (which are in the
same cluster).
3. Assign point y to a new cluster.
4. For all remaining points in the original cluster identify whether
they are nearer to x or y.
5. Assign points nearest to y to the new cluster (cluster containing
point y)1.
6. Repeat steps 1-5 until desired number of clusters is reached.
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A C program was written to perform cluster analysis (see Appendix B).
There was no obvious choice for the number of clusters to generate so
steps of five were initially used. Later cluster sizes of 1, 2 3, 10, 30, 100
and 300 were used in order to cover a wide range of cluster sizes.
Clustering does not readily lend itself to prediction. The method used
to evaluate its potential as a predictive method was as follows: the
full set of compounds was clustered into n clusters; the clusters were
then categorised as predictive of asthmagens or controls on the basis
of the relative proportions of each in the cluster (see Equation 2.2).
For example, if a cluster had more asthmagens in it than would be
expected given the ratios of asthmagens to controls in the full dataset,
that cluster was deemed predictive of an asthma hazard. A 2x2 table
of prediction activity versus observed (true) activity was then created
and a kappa1 value calculated (see Equation 2.5).
T? V P 17nrV J?n — TOTALasthmagens A T
TT/Uasifirnageris , „ . \ X i (7J flL/cluster
{J-*- A.L/asthmagens+TOTALcontrois)
(2.2)
The source code of the program to Guenoche cluster and calculate a
kappa value is included on the accompanying CD-ROM (see Appendix
B).
X2 Testing of Clusters
The X2(chi-squared) test was applied as a crude measure of the predic¬
tive performance of clustering. As with other applications of two by 'n'
tables, x2 can be calculated to see if the independent variable (in this
xIt is possible that none of the remaining points are closer to y than x. In such a
case y would be in a cluster by itself.
'Note a true kappa value as it is not calculated with a validation dataset, rather
a kappa based on the learning dataset.
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case the fragment) is associated the dependent variable (reported sen-
sitisation hazard). (It should be noted that an a priori assumption has
been made. The x2 value is merely a measure of association and does
not indicate which variable is the dependent or independent.) The x2
test involves calculation of the expected cell frequencies in the two by
two table. If Ea, Eb, Ec and Ed refer to the expected cell values for a, b,
c and d respectively then:
_ (a + b) x (a + c)
a
(a + b + c + d)
(o -T b) x (b + d)
(o T b -(- c -h d)
(a + c) x (c + d)Eo = — —
(ft -|- b c T d)
(b + d) x (c + d)
(a + 6 + c + d)
The x2 value is given by the Equation 2.3.
2 (Observed — Expected)2 (a — Ea)2 (b — Eb)2 (c — Ec)2 (d — Ed)2
^
Expected Ea Eb Ec Ed
(2.3)
For a two by two table there is just one degree of freedom (rather than
three) since the expected values are calculated from the marginal totals
resulting in the loss of two degrees of freedom. The computer package
Epi-Info1 was used to calculate both the 2x2 x2and the x2 for trend.
1Public domain software available on the cdrom (see Appendix B)
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Hazard Odds Ratios
An Odds Ratio for the Hazard (or HOR) was used to characterise sub¬
structure fragments. This was the ratio of the two odds - the odds of
a chemical being a reported causative agent given the presence of the
substructure fragment; compared to the odds of a chemical being a case
given the absence of the substructure fragment in question.
This is given by the equation:
HOR = Til (2.4)b a
where a, b, c and d are described in Table 2.7.
The calculation of HOR's was done using the Epi-Info statistical com¬
puter program package available from the Centers for Disease Control,
Atlanta, Georgia, USA. The Exact Method was used when low expected
occurrence frequencies caused the Cornfield confidence limits to be un¬
reliable. HOR's were calculated with upper and lower 95% confidence
intervals (C.I.s). A HOR was deemed significant if the range between
the lower and upper 95% confidence intervals excluded the value 1.00.
The range of value an odds ratio can take is between 0 and infinity.
Confidence intervals for odds ratios can be calculated by a number of
methods. The simplest involve approximations of the probability dis¬
tribution such as that used in the Taylor Series. Two methods of calcu¬
lation of 95% C.I.'s were used.
HOR's by Occurrence Frequency \;2 for Trend
Were HOR's are calculated for different occurrence frequencies these
refer to the odds of a chemical being a reported causative agent given





Contains y a bb
Fragment n c dd
Table 2.7: 2x2 table for odds ratio calculation.
the presence n occurrences of the substructure fragment; compared to
the odds of a chemical being a case given the absence of the substruc¬
ture fragment in question. Where a y2 for trend is calculated, this was
done using the Epi-Info package (see Appendix B).
Taylor Series
The approximate method uses the equation:
were 1.96 is the z value used for C.I.'s of 95%. This method is known as
the Taylor Series. The Taylor Series method is inappropriate for data
in which any of the expected cell values in the 2x2 table are small. It
provides satisfactory results when expected cell values in the two by
two table are not less than 5.
Fisher Exact Method
The need for an exact method of confidence interval (C.I.) measurement
arises when cell values in the two by two table (Table2.7) are small
such that expected values (see Table 2.8) are less than 5. In Table 2.8
if we consider the marginal totals (mi, m0, rq, n0) as fixed then for any
change in Ea the values for the other three cells can be calculated. The
statistical theory underlying exact testing is conditional on these fixed
marginals. The calculations were performed by the Epi-Info statistical
package.
1.96X
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Predicted 1 a b
0 c d
Table 2.9: 2x2 table for test agreement.
Test Agreement Statistics
Kappa values for the predictive value of clustering and logistic regres¬
sion models were calculated to indicate the model agreement with ob¬
served data (See Equation 2.5) [168].
(L-\rd Ea-\-Efi
- = 1 _eJL (2-5)1
N
where
a = number of predicted cases that are true cases
d = number of predicted inactives that are true inactives
Ea = expected number of true cases
Ed = expected number of true inactives
N = total of all cases and all inactives
The values a and d along with their complementary expected values
are derived from Table 2.9.
Kappa values below 0.4 indicate poor agreement; values between 0.4
and 0.5 indicate moderate agreement; a value between 0.5 and 0.6
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indicate acceptable agreement; a value between 0.6 and 0.8 indicates
good agreement; and values above 0.8 indicate excellent test agreement
[168],
Logistic Regression
Logistic regression analysis is similar to ordinary linear regression,
the principal difference being that the variables being modelled are
discrete rather than continuous. In this study the modelled variable is
sensitizing activity - true (1) or false (0). The independent variables (in
this study the fragment occurrences) can be continuous. The resulting
dependent variable (the prediction ofactivity) takes a continuous value
between 0.0 and 1.0.
The logistic regression equation for each of the 1 to TV fragments the




I _|_ e(a+/3ixi+(32X2+ ....+/3kxk) (2.6)
Where a = a constant
Pi = the logistic regression coefficient for fragment 1
xi = the number of occurrences in the molecule of fragment 1
P2 = the logistic regression coefficient for fragment 2
x2 = the number of occurrences in the molecule of fragment 2
etc...
Pk = the logistic regression coefficient for fragment k
Xk = the number of occurrences in the molecule of fragment k
Logistic regression analysis was performed using the Statistical Pack-
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age for Social Scientists (SPSS, from SPSS Inc.) package1. Data were
entered in the package in the form of an ASCII file containing a line
of information for each compound (See Table 2.6). Each line (or row)
contained the chemical name, the activity (coded as 0 or 1 for control
or active respectively) and a list of fragment occurrence frequencies.
Although in excess of 130 substructure fragments were available the
limit for SPSS was 60 and therefore a reduced set was used. The 60
chosen were selected after consideration of the HOR results.
A model was obtained using a backward stepwise method. The sig¬
nificance of the 'likelihood ratio' was used to determine which inde¬
pendent variables remained in the model. Variables were entered and
removed from the model on the basis of an entry probability of 0.05 and
a removal probability of 0.10. The Wald statistic was not used. Other
model methods and parameters were tested but are not described.
The models were tested using a kappa test statistic based on the num¬
ber of compounds with predicted hazard greater or less than a given
threshold. The standard threshold was 0.5 although the effect of using
other threshold levels on the kappa statistic was studied. An iterative
process of improving the model by adjusting the fragments was used
(see Figure 2.8)
Sensitivity and Specificity Sensitivity and specificity are mea¬
sures used to evaluate the effectiveness of screening / diagnostic tests.
Since the prediction of a hazard value for chemicals is in effect a screen¬
ing test sensitivity and specificity are an appropriate additional mea¬
sure of prediction model performance. Since the logistic regression ap¬
proach yields a hazard index value (between 0 and 1) which is a prob¬
ability of activity it can be useful to specify a threshold value (particu¬
larly if a test agreement statistic, kappa, is required). By adjusting the

















Figure 2.8: Logistic regression model was refined by adjustment of the frag¬




Test y a b a+b
status (T) n c d c+d
Marginal Totals a+c b+d
Sensitivity — Probability (T+\S+) = r
(a + c)
Specificity = Probability(T \S ) = ^ ^ ^
Table 2.10: Sensitivity and specificity. (After Hennekens and Buring [1, page
331]).
threshold to a lower or higher value one can alternatively increase sen¬
sitivity (and decrease specificity) or increase specificity (and decrease
sensitivity). To quantify sensitivity and specificity, values were calcu¬
lated using the formulae described in Table 2.10.
Creation of A Final Model
The final prediction program was developed from the existing fragment
tabulating programs. The program takes aMDL molfile format connec¬
tion table and calculates a likelihood of the compound being an asth-
magen using a logistic regression equation.
The interface to the program was web based. The program is accessed
via a web page into which the molfile of the chemical in question is
pasted. The web based interface allows the program to be accessed
from any computer architecture that supports a web browser (indeed
a graphical user interface to the web browser is not essential). An ad¬
ditional advantage of a web based interface is that users do not have
direct access to the program and that the program can be readily up-
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dated as improvements are made. Finally, the possibility to monitor
and restrict access to the program is available using this method.
The final model has been implemented as a world wide web (Internet)
accessible program on a SGI Indigo2 web server. The hazard prediction
program was written in ANSI standard 'C' code and implemented as a
cgi-bin program on the web server. Its URL is
http://www.bch.ed.ac.uk/cgi-bin/hazassess
and the W3 method used is the 'POST' method. The model is also avail¬
able on the cdrom (see Appendix B).
The model may be used by users from any Web capable operating sys¬
tem however the creation of the molfile connection tables is dependent
on a suitable chemical structure drawing package unless the molecules
are small in which case a connection table could be manually created h
The user of the hazard assessment program is expected to create a
molfile connection table for their molecule (See Figure 2.4). Full in¬
structions of where to obtain the appropriate software are included
with the package.
An interface was designed to allow standard molfile connection tables
to be pasted into a HTML Form (see URL
http://www.bch.ed.ac.uk/~james/progs/2
A text input was preferred because it allows access to the prediction
program from non-graphical browsers. The model returns a hazard
index for the compound and checks the database to determine whether
the compound was an asthmagen or control in the original dataset.
1Users ofWindows (3.11, 95, 98, NT) and Macintosh users can download copies of
MDL's IsisDraw package which is available without charge to academic or individual
home use from URL http://www.mdli.co.uk/






The results will be presented in five parts: 'collected data'; 'clustering';
'hazard odds ratios'; 'logistic regression'; and 'validation'. The data col¬
lection part will summarise the amount of data collected and present
important epidemiological relationships noted. The clustering will be
dealt with briefly as the methodology was dropped before the skin sen¬
sitizers were analysed. The hazard odds ratio and logistic regression
section will each be subdivided into two subsections: the first and ma¬
jor subsection will look at how asthma compounds were differentiated
from control compounds; and the second subsection will cover the re¬
sults of methods used to differentiate between asthmagens and skin
sensitizers. The final part, the validation, will include the results from
the validation of the predictive model (developed from the logistic re¬












Overview of the Increase in Published Literature (Source Medline)
'occupational dermatitis'.tw —$—
'occupational asthma'.tw • ■ +■







66-70 71-75 76-80 81-85 86-90 91-95
Sample period (in 5 year steps between 1966 and 1995)
Figure 3.1: Number of papers yielded per 5 year period using particular
textword search phrases in the MedLine database.
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Category Number of Molecular Mass
of Compound Compounds Median Lower Upper
Controls 302 118 89 187
Asthmagens 82 211 66 327
Skin sensitizers 200 207 143 290
Table 3.1: Number of chemicals and molecular mass distribution in each
category of compounds.
(Upper and lower values refer to quartiles.)
3.1 Collected Data
The number ofpublished papers using the phrases 'occupational asthma'
and 'allergic contact dermatitis' has markedly increased over the last
three decades (see Figure 3.1). Over the same period there is infre¬
quent use and no notable increase of the phrase 'occupational dermati¬
tis'.
In this period 1966-1994 a total of 821 asthmagens (see Appendix C.l)
were identified by critical appraisal of published literature which sat¬
isfied the study criteria (see p50). CAS Registry Numbers were found
for 77 of the active compounds and a structure was identified for all of
them. Some compounds reported in the published literature as asth¬
magens failed to satisfy the full study criteria needed to be included in
the analysis (see Appendix C.l). In addition 200 skin sensitizers2 were
identified and tabulated (see Appendix C.2). These data along with
molecular mass distributions are summarised in Table 3.1.
1Since there was an overlap between the data collection and the preliminary data
analyses some of the results that follow will indicate that less than 82 asthmagenic
compounds were used. This occurred solely because all asthmagens had not at that
point been identified and verified as satisfying the study criteria.
2A limit of200 skin sensitizers was set for the purposes of the study although more
than 200 occupational skin sensitizers are known.
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Clinical and Epidemiological Data
Data deemed to be of potential epidemiological relevance was tabu¬
lated and database created. An example of the data available for each
compound is given in Table 3.3. Several data fields have not been in¬
cluded as no data was found for this particular compound. These in¬
clude symptom fields for cough, chest tightness, conjunctivitis, nasal
symptoms, headache. For a large number of the fields data was too
sparse to allow effective evaluation.
A large proportion of the asthmagens (31) were identified as hazards
on the basis of single case reports, with over half the compounds (48)
having 3 or fewer cases recorded. Twenty-two compounds had between
3 and 33 cases reported and eight compounds had in excess of 33.
The commonest literature case reports of OA were due to toluene di-
isocyanate, plicatic acid (from Thuja plicata, Canadian Western Red
Cedar and Thuja occidentalis, Eastern White Cedar), phthalic anhy¬
dride, formaldehyde and abietic acid (found in colophony). These preva¬
lence data represent minimum values.
Reported evidence for an IgE-mediated response was found in only 23
compounds, of which only 17 reported specific IgE (see Table 3.4). The
median molecular mass for the 17 compounds for which specific IgE
was noted was 206 (inter-quartile range 164-422). This was not sig¬
nificantly1 different from the median molecular mass (265.91, 98-349)
of the 11 compounds for which no evidence of an IgE mechanism was
found when sought.
The type of asthmatic response noted varied greatly (see Table 3.5).
Five compounds (azodicarbonamide; hexamethylene di-isocyanate; toluene
di-isocyanate; plicatic acid; and a trimer ofhexamethylene di-isocyanate)
were reported as producing all three response types - immediate, late
Significance tested using a non parametric test, the two sample Mann-Whitney
test as described Eason et al. [169]
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Name: Tetrachloroisophthalonitrile
CAS Registry No.: 1897-45-6
Synonyms: Chlorothalonil; 2,4,5,6-Tetrachlorol,3-benzene-
dicarbononitrile; Daconil; Dac-2787; Bravo;
Forturf; ExothermTermil; Termil
General Notes: USE - A fungicide, bactericide, nematocide.
Agricultural and horticultural fungicide. [MERCK]
Sensitisation Single case report by Honda et al..
notes: Atopy defined by positive scratch test to just
one of several common allergens. No elevated




Physical Data Physical form: solid
Melting point: 250 °C
Boiling point: 350 °C
Vapour pressure: No data available
Water solubility: Practically insoluble
Epidemiological Asthma absolute prevalence Single case
Data Asthma % prevalence: Not available
Basis of diagnosis: Challenge tested
Asthma response type: Dual
Sensitising concentration: < 1/j,mole/litre of air
IgE involvement: No evidence found
Latency: 1 year
Persistence of asthma: Not available
% of atopic cases: 100%
Other symptoms: Wheeze: Yes
Dyspnoea: Yes
....other symptoms
Table 3.3: Example of a Database Entry.
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Evidence for an Compounds
IgE Mechanism
IgE sought but Furfuryl alcohol; Ethylene-diamine; Hy-
not found dralazine; Isophorone di-isocyanate; Ethy¬
lene oxide; Tetrachloroisophthalonitrile; Abi-
etic acid; Captafol; Hexachlorophene; Biuret
of hexamethylene di-isocyanate; Dobutamine
hydrochloride
Elevated levels of Hydroquinone; Carmine; Tetracycline; Tetra-
Total IgE zene; Adipic acid; Methyl blue
Specific IgE found Phthalic anhydride; Trimellitic anhydride;





<l,3,5>triazinane-2,4,6-trione ; Plicatic acid;
Black GR Reactive Dye(BK-5); Orange-GR
Reactive Dye; Red-BBN Reactive Dye ;
Phenylglycine acid chloride; MM22383;
Table 3.4: Asthma Compounds and Associated Immunoglobulin-E (IgE)
Mechanism.
Note: Assignment of a compound to a category in the table indicates a mini¬
mum for information available. For example the observation that non-specific
levels of IgE are elevated does not preclude there being specific IgE present.




Immediate 3-Carene; Styrene; Trimellitic anhydride;
Isoniazid; Amprolium hydrochloride; Chlor-
hexidine; trientine; 7-Amino cephalosporanic
acid; Tetracycline; Hexachlorophene; Methyl blue;
Cephalexin; Phenylglycine acid chloride;
Late Formaldehyde; Furfuryl alcohol; Glutaraldehyde;
Methylmethacrylate; Hydralazine; Isophorone
diisocyanate; Methyl-2-cyanoacrylate; a-Methyl
DOPA; Salbutamol; Acetic acid; 6-Amino penicil-
lamic acid; Ampicillin; Benzyl penicillin; Cimetid-
ine; Sodium iso-nonanoyloxybenzene sulphonate;
Hexamethylene tetramene; Tetrazene; Glycyl
compound; Fenthion
Immediate or Late Paraphenylene diamine; diphenylmethane di¬
isocyanate; Aminophylline
Dual Himic anhydride; Hexahydrophthalic anhydride;
Tetrachlorophthalic anhydride; Dimethylethanol-
amine; Tetrachloroisophthalonitrile; Captafol;
Carmine; Pauli's Reagent; Sulfathiazole; Adipic
acid;
Immediate or Dual Pyromellitic di-anhydride; Abietic acid; Biuret of
hexamethylene di-isocyanate; Black GR Reactive
Dye (BK-5); Orange-GR Reactive Dye; Red-BBN
Reactive Dye;
Late or Dual Maleic anhydride; Phthalic anhydride; Ethylenedi-
amine; Piperazine; Aminoethylethanolamine; 1,5-
Naphthalene diisocyanate; Ethyl cyanoacrylate;
Chloramine-T;
Immediate, Late or Dual Azodicarbonamide; Hexamethylene di-isocyanate;
Toluene diisocyanate; Plicatic acid; l,3,5-tris-(6-
isocyanato-hexyl)-<l,3,5>-triazinane-2,4,6-trione;
Table 3.5: Asthmagens by Asthma Response Type(s).
Note: Assignment of a compound to a category in the table indicates a mini¬
mum for information available. For many of the compounds the information
is based on just one or two papers.
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and dual responses albeit in different cases. A late response was ob¬
served (in at least some of the cases) with over half the compounds. A
late response alone was seen with a quarter of the compounds. Only a
third of the compounds caused immediate responses, and of these less
than a fifth produced only an immediate response. Notably, no com¬
pounds for which specific IgE was observed caused solely a late asth¬
matic response. Compounds that did cause late responses for which
specific IgE was noted also caused dual type responses1.
Specific IgE was consistently found among the acid anhydride and re¬
active dye classes of asthmagens when sought. Furthermore, dual re¬
sponses were noted (in at least some patients) for all acid anhydrides
and reactive dyes.
The symptoms associated with sensitisation varied with chemical group:
persons sensitized to acid anhydrides exhibited symptoms of wheeze,
dyspnoea, rhinitis/rhinorrhea and cough. Skin and mucus membrane
irritation were also noted though these are known irritant symptoms
of acid anhydrides. Evidence for an IgE mechanism (either as raised
serum levels or identification of specific IgE) was present in most cases
of asthma due to anhydrides. Isocyanate asthma presented with symp¬
toms ofwheeze, dyspnoea, chest tightness, cough, rhinitis, runny eyes
and skin irritation.
Nasal symptoms, described variously as rhinitis or rhinorrhoea were
evident (in at least individual) for over half (38) the sensitising com¬
pounds. Other less common symptom, for example headache, were
noted with formaldehyde, glutaraldehyde, triethylene tetramine, and
hexamethylene tetramine.
1This is not to say immediate or late responses were not also seen.
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3.2 Clustering
Prior to the start of this study some collaborative work between Dr Ag-
ius (The University of Edinburgh) and Dr GeoffDowns (formerly with
The University of Sheffield, now with Barnard Chemical Information
Ltd.) had been undertaken looking at clustering patterns ofa dataset of
asthma and control compounds. The first part of the clustering results
relate to this collaboration. Clustering was performed by Dr Downs us¬
ing software that was not readily available. The second part illustrates
how clustering was used on the complete dataset. The clustering was
performed using a C program written for the purpose1. The program
and the output of the clustering can be found on the CD-ROM (see Ap¬
pendix B). Clustering as a method was used only briefly in this work
as it was super-ceded by other methods. It was not used to distinguish
between skin and respiratory sensitizers.
The preliminary dataset contained 29 asthmagens and 29 controls (see
Table 3.6) [164]. One control (tetrachloroisophthalonitrile) was later
reclassified as an asthmagen. The results of clustering this dataset us¬
ing different cluster sizes and methods are shown in Table 3.6. The
clustering was performed by Dr G. Downs (Barnard Chemical Informa¬
tion Ltd.) using Ward, Guenoche, and Jarvis-Patrick clustering meth¬
ods. The clustering was performed blind - Dr Downs did not know
which compounds were asthmagens and which were controls. The
Guenoche algorithm appeared to be effective with this dataset (par¬
ticularly with few clusters) and, after consultation with Dr. Downs, the
Guenoche method was adopted as the method to use for the remainder
of the study.









Dibenzoyl peroxide Himic anhydride
2-Hydroxypropyl acrylate Phthalic anhydride
Dimethoxy methane Trimellitic anhydride
Oxalic acid Hydroquinone
Hexan-2-one Methyl methacrylate
Butyl acetate Pyromellitic di-anhydride
or£/m-Toluidine Ethylene diamine






2,4,6-Trinitro toluene Hexamethylene di-isocyanate
Nitro aniline 2,4-Toluene di-isocyanate
Nitro methane n-Methyl DOPA
1,2-Dinitro propane N-Methyl morpholine
ortho-Acetyl salicylic acid Methyl cyanoacrylate
2,2'-Imino diethanol Ethyl cyanoacrylate
Dimethyl formamide Diethyl ethanolamine
2-Pyridyl amine 1,5-Naphthalene di-isocyanate
Diphenyl amine Isophorone di-isocyanate
2-Dimethyl aminoethanol
Methyl-phenyl di-isocyanate
Table 3.6: List of control and asthma compounds used by Dr. G. Downs for
the cluster analyses. .
Originally the data set consisted of 29 asthmagens and 29 controls but one of
the controls was later found to be an asthmagen. * Note: Hydrazine does not
contain carbon and so does not appear elsewhere in this thesis.
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No. ofClusters Ward Guenoche Jarvis-Patrick
10 0.19 0.50 0.31 (9)
15 0.57 0.56 0.47 (16)
25 0.70 0.77 -
30 0.70 - 0.70 (30)
Table 3.7: Kappa values for predicting asthma hazard.
The k values derive from predictions made using the Ward, Guenoche and
Jarvis-Patrick methods of clustering. The number of clusters cannot be se¬
lected using the Jarvis-Patrick method so the k for nearest number of clusters
is given (in brackets). The set of data included 31 asthmagens and 29 controls
(one of the controls was found to be an asthmagen after the compounds were
initially selected).
The final dataset for clustering consisted of 75 asthmagens and 302
controls. A Guenoche clustering of the 75 asthmagens of the complete
set was performed using the descriptors of the type 2 fragment set (See
p62). The clustering was performed twice: once with descriptors as
continuous1 variables; and then with descriptors coded in binary2 form.
Figure 3.2 shows the results of clustering 14 times (to produce 15 clus¬
ters) using the continuous method. The values in parenthesis are the
asthmagen:control ratio. It can be seen that the clustering is not even,
indeed cluster 2 contains 207 of the original 377 compounds. The start¬
ing ratio of asthmagens to controls was approximately 1:4. A similar
ratio would be expected in the clusters if the method was not distin¬
guishing between asthmagens and controls. Several clusters, including
cluster 2, appear to markedly differ from this ratio. Clusters 2 and 8
are 'control' clusters. The 'asthmagen' clusters such as 1, 3, 5, 7 and 9
have very few compounds. The kappa value for this clustering set was
0.38.
Performing the same cluster procedure as above on the same data but
xThe fragment frequency of occurrence in each molecule (rather than just fragment
presence or absence) was a determining factor in the clustering.
2A logical form where a 0 means the fragment is absent and a 1 indicates presence.
This form is simplistic in that it only recognises presence of a fragment in a given











2 12 8 13 4







Figure 3.2: Hierarchical Structure of the Guenoche Continuous Cluster
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Figure 3.3: Hierarchical Structure of the Guenoche Binary Cluster
The asthmagen:control ratio is given in parenthesis.
using a binary cluster method a slightly more even spread of data (see
Figure 3.3). The largest cluster (cluster 11) contains 125 compounds.
Clusters 5 and 15 contain only control compounds. Cluster 5 has at
least one halide in 29 of its 31 compounds. The only strong 'asthmagen'
cluster is cluster 9. Although the binary cluster method produced a
more even clustering, it produced fewer 'asthmagen' clusters than the
continuous method. The kappa value for this clustering set was 0.41.
The compounds contained in each cluster are available on the CD-ROM
(see Appendix B).
A number of cluster runs were performed using both the binary and the
continuous method but varying the number of clusters. The results are
shown in Figure 3.4. There is little difference between the two methods
93
Figure 3.4: Effect ofCluster Size on the Kappa Value ofGuenoche Clustering
of 75 asthmagens and 302 controls.
except when fewer clusters are selected. When 15 or fewer clusters are
selected the binary method produces the better kappa value.
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3.3 Hazard Odds Ratios
Chemical Substructure Fragments Associated with
Asthma Hazard
Seventy-six known respiratory sensitizers (asthmagens) were compared
with 303 control compounds. Using the data contained in the frag¬
mentation tables, Hazard Odds Ratios (HOR'S) were calculated (see
page 73). The odds ratio for a particular frequency of occurrence n is
given by the odds of a compound containing n fragments (of a specified
type) being asthmagenic over the odds of a compound containing no
fragments (of the same type) being asthmagenic.
The HOR's and 95% C.I. for 130 Type 1 fragments (see p62) were cal¬
culated automatically. The results are shown in Table 3.8. The HOR's
refer to discrete fragment occurrence frequencies.
There is evidence that hazard increases with occurrence frequency in
the compound for certain fragments (see fragments 7, 14, 15,16, 18, 27,
28 and 30 in Table 3.8). These fragments predominantly contain oxy¬
gen and / or nitrogen atoms. Several fragments have high HOR's for a
single occurrence - these include the ethanolamine fragment (19), the
1,2-diaminoethane fragment (21), the furan fragment (20), the azine
fragment (25), the thio-ether (37) and the acid anhydride fragment
(34). The carbon-carbon single bond fragment (1) produces a statis¬
tically significant HOR at a frequency of 5 in a compound.
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Table 3.8: Hazard Odds Ratios for Type 1 Fragments. An
'E' next to the 95intervals indicates an exact method was




































8 5 3.42 1.91-6.12
1 3.42 1.08-10.83
9 3 2.36 1.33-4.17
5 3.85 1.61-9.19
2 2.33 1.08-5.02
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1 26.26 3.07-1211.71 E
34
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1 14.24 4.10-61.91 E
37
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Chemical Hazard Upper & Lower
Substructure Environment Odds 95% Confidence
Fragment Ratios Intervals
Any 2.76 1.40-5.63
Oxygen Aliphatic 2.63 1.40-5.01
Aromatic 2.11 1.04-4.76
Any 5.56 3.12-9.95
Nitrogen Aliphatic 6.29 3.53-11.24
Aromatic 2.84 1.49-5.40
Any 4.26 2.05-8.82
Sulphur Aliphatic 3.68 1.66-8.09
Aromatic 13.43 3.21-78.4
Any
Chlorine Aliphatic 0.28 0.07-0.81
Aromatic
Table 3.9: Chemical elements with statistically significant hazard odds ra¬
tios.
(Asthmagens compared with controls).
The general HOR (for any occurrence) provides a useful measure of
fragment hazard. Table 3.9 shows the HOR's for presence of atoms in
either aromatic or aliphatic environment1. It should be noted that ni¬
trogen atoms are more hazardous when in an aliphatic environment
whereas sulphur atoms appear more hazardous in an aromatic envi¬
ronment. The hazard presented by oxygen atoms does not vary greatly
between the two environments. The presence of halogens was asso¬
ciated with a lower than average OA hazard as halogen atoms were
heavily represented in the control set. The HOR for the presence of
aliphatic chloride atoms was 0.28 (0.07-0.81) and for aliphatic bromine
was 0.00 (0.00-1.57, not listed in the table as it is not statistically sig¬
nificant).
When the HOR's for type 2 fragments are ranked in order, the frag¬
ments based on isocyanate, (3-lactam ring, acid anhydride, ethanolamine
1An atom was deemed to be in an aromatic environment if it formed part of an
aromatic ring or if one of its immediate neighbour atoms (to which it was bonded)




Upper & Lower 95%
Confidence Limits
Isocyanate oo 6.25-oo
(3-lactam ring CO 6.25-oo
Acid anhydride 30.64 3.71-1385
Ethanolamine backbone N-C-C-0 19.93 6.07-83.8
Acrylate derivative 13.04 2.25-135
Imine C-NH-C 8.24 3.47-19.8
Carboxylic acid -COOH 5.48 2.25-13.37
Any double bond X=X 3.77 2.01-7.17
Carbonyl 3.15 1.82-5.47
Table 3.10: Statistically significant hazard odds ratios for chemical substruc¬
ture fragments.
These are Type 2 (see p62) fragments. (Asthmagens compared with controls)
and acrylate groups all present HOR's indicating a greater than tenfold
increase in the likelihood that compounds containing them are an OA
hazard (see Table 3.10).
HOR's for type 2 fragments were examined for increasing fragment
occurrence rates. Significant HOR's were noted for both aliphatic and
aromatic occurrences of the following hetero-atom types: nitrogen, oxy¬
gen, sulphur (see Table 3.11). The presence of two or more imine or
carbonyl groups presented a significant OA hazard whilst a single oc¬
currence was not significant .
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Fragment Fragment Occurrence Rate
1 2 3 > 4
Aliphatic oxygen 1.13 2.33 5.41 2.60
Any amine 2.55 16.04 23.39 oo
Aromatic carbonyl 2.46 4.38 oo oo
Aromatic nitrogen 1.49 3.27 9.81 0.00
Ethene derivative 2.79 3.26 2.68 5.58
Imine derivative 2.52 13.43 oo oo
Carbonyl 1.16 7.33 oo oo
Any nitrogen 2.35 6.71 14.53 22.71
Any oxygen 1.18 2.33 4.90 2.03
Any double bond 1.29 3.10 10.36 14.25
Table 3.11: Hazard odds ratio by frequency of occurrence ofType 2 substruc¬
ture fragments.
(Asthmagens compared to controls, statistically significant (at 5% level)







Aliphatic Oxygen 2.42 1.13-5.51
Aromatic Sulphur 3.12 1.05-9.04
Carboxylic Acid 7.14 2.45-22.21
Aliphatic Carboxylic Acid 7.57 2.44-25.67
/3-lactam 6.81 1.38-43.06
Acid Anhydride 24.57 3.00-1113.17
Table 3.12: Hazard odds ratios to differentiate between skin and respiratory
sensitizers.
Using Hazard Odds Ratios to Differentiate between
Skin and Respiratory Sensitizers
Fragment tables were created for the 58 asthmagens (which were not
skin sensitizers) and 179 skin sensitizers (which were not asthmagens).
Hazard odds ratios and y2 tests for trend were calculated for the ex¬
plicit set of 48 Type 2 fragments plus an additional X-C-C-X fragment
(where X could be oxygen or nitrogen1).
Seven fragments had significant HOR's for occurrence (see Table 3.12)
and thirteen fragments had statistically significant linear trends (p
value <0.05, see Table 3.13). A strong linear trend is seen with the
carboxylic acid fragment. All of the listed HOR's had a significant p
value for trend except the aromatic sulphur fragment . It should be
noted that the presence of an acid anhydride fragment is nearly 25
times more likely to occur in a asthmagen than a skin sensitizer (Table
3.12).




Aliphatic Nitrogen 4.05 P == 0.044
Oxygen 8.12 P == 0.004
Aromatic Oxygen 3.97 P == 0.046
Aliphatic Oxygen 6.05 P == 0.014
Aromatic Chlorine 6.96 P == 0.0084
Carboxylic acid 20.16 P == 0.00001
Aliphatic carboxylic acid 19.43 P == 0.00001
Any double bond 6.41 P == 0.011
C=N (double bond) 6.54 P == 0.011
C=0 (double bond) 5.81 P =- 0.016
Aromatic C=0 4.51 P == 0.034
(3-lactam 9.04 P == 0.0026
Acid anhydride 17.10 P == 0.00004
Table 3.13: Linear trend for fragments in the model differentiating between
the skin and respiratory sensitizers.
A positive trend for a fragment favours classification as an asthmagen as the
occurrence of that fragment increases.
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3.4 Logistic Regression
Logistic regression models were created from the fragment data using
a backward stepwise method with each iteration being tested by the
log likelihood ratio statistic (see p77). Three models will be described
here: the first model is based on the asthmagen and control dataset
and it was used for the majority of the plotted data; the second model
was used to predict between skin and respiratory sensitisation; finally,
the third model is used in the programs available on the accompanying
CD-ROM (see AppendixB). Results will refer to the first model unless
stated otherwise.
The first logistic regression model was created using a dataset of 75
asthmagens and 302 controls. The logistic regression program had a
limit of 50 on the number of variables that could be entered for logis¬
tic regression analysis. This precluded the use of the type 1 fragment
dictionary and so selected type 2 fragments were used. The predictor
fragments and their coefficients are shown in Table 3.14. Positive (3 co¬
efficients indicate that a fragment is associated with increased asthma
hazard. Negative (3 coefficients indicate that a fragment plays a 'pro¬
tective' role. The standard error is a measure of how wrong the frag¬
ment coefficient can be. A large [3 coefficient will generally produce
a large standard error unless a fragment has decisive effect on activ¬
ity. The model has two large magnitude (3 coefficients (for the ketone
and the aldehyde fragment groups). The standard error for these two
coefficients is also very large. The acid anhydride and the isocyanate
fragments also have large /3 coefficients but the standard errors are
relatively small. The significance of the log likelihood ratio is the pa¬
rameter which determines whether a fragment remains in the model1.
Note the aldehyde fragment has the least significant log likelihood ra¬
tio.
1A11 fragments start in the model with the backward stepwise method, they are
then removed if their contribution is not significant.
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Fragment (3 Standard Significance of the
coefficient Error log likelihood ratio
Carbonyl 14.36 164 0.0043
Isocyanate 5.74 21.6 < 0.0001
Acid anhydride 5.23 1.20 < 0.0001
Aerylate 2.81 0.99 0.004
Aliphatic carboxyl 2.00 0.58 0.0009
Amine 0.99 0.36 0.0037
Carbon - 0.61 0.16 < 0.0001
Aromatic nitrogen - 0.64 0.34 0.0410
Ether - 1.00 0.46 0.0148
Benzyl - 1.02 0.48 0.0305
Aliphatic oxygen - 1.11 0.28 < 0.0001
Aromatic chlorine -2.07 0.49 < 0.0001
Aliphatic chlorine - 2.27 0.51 < 0.0001
Aliphatic sulphur - 2.36 0.66 0.0004
Phosphorus -3.24 1.28 0.0009
Amide -3.46 1.45 0.0053
Aliphatic fluorine -7.13 23.3 0.0035
Aliphatic bromine -9.93 24.7 < 0.0001
Aldehyde -12.21 164 0.0561
MOLECULAR MASS 0.066 0.01 < 0.0001
CONSTANT a -4.30 0.5 —
Table 3.14: Logistic regression model differentiating between asthmagens
and control chemicals.
The variables a and j3 correspond to the constant and coefficient of the logistic
regression equation. See Appendix D.2 for details of the values shown.
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The hazard prediction given by the logistic regression model for a par¬
ticular compound is dependent on the correct classification of the com¬
pounds in the learning dataset. The reliability of this classification
may be related to the 'method of diagnosis' and/or the 'prevalence' of
OA to each learning dataset compound. Hazard predictions based on
the model were made for each compound in the learning dataset and
these predictions were then plotted against 'method of diagnosis' (see
Figure 3.5) and 'prevalence' (see Figure 3.6). Figure 3.5 demonstrates
that the model prediction is higher for those compounds identified in
the literature as asthmagenic on the basis of respiratory challenge.
Similarly, Figure 3.6 demonstrates that model predicts lower hazard
values for those compounds cited as asthmagenic in single case reports
only.
A number ofcompounds were misclassified by this first regression model.
The active compounds that were most seriously misclassified (that is
with predicted hazard less than 0.25) were: 2-diethyl-ethanolamine
(predicted hazard 0.22); styrene (0.02); para-phenylene diamine (0.17);
dimethylethanolamine (0.21); N-methylmorpholine (0.08); hydroquinone
(0.04); 3-carene (0.09); 2-methyl-3,5-dinitro benzamide (0.18); captafol
(0.20); phenyl glycine acid chloride (0.15); fenthion (0.15); acetic acid
(0.12); ethylene oxide (0.01); chloroxylenol (0.08); and furfuryl alcohol
(0.01).
The control compounds that were seriously misclassified (that is with
predicted hazard greater than 0.75) were acetic anhydride (predicted
hazard: 0.83); 2,2'-iminodi(ethylamine) (0.90); hexahydro-l,3,5-trinitro-







































Figure 3.5: Scatter plot showing the predictive performance of the logistic
regression model (by method of diagnosis of occupational asthma).
Each point represents one chemical. Horizontal lines indicate median value.
The Y axis represents predicted hazard in the range 0 (no hazard) to 1 (max¬
imum hazard). Challenge refers to whether diagnosis of a chemical as an
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Figure 3.6: Scatter plot showing the predictive performance of the logistic
regression model (by prevalence of occupational asthma).
Each point represents one chemical. Horizontal dotted lines indicate median




Skin Asthma % Correct
Skin 169 11 93.89%
Asthma 20 37 64.91%
Overall 86.92%
Table 3.15: Classification table for the logistic regression model differentiat¬
ing between skin and respiratory sensitizers.
Distinguishing Between Skin And Respiratory Sen¬
sitizers Using Logistic Regression
In the same way that a logistic regression model was developed to dis¬
tinguish between actives from controls for OA, it is possible to develop
a model to discriminate between skin and respiratory sensitizers. This
was done because it proved impossible to produce a valid set of controls
for skin sensitizers. (There is no suitable equivalent of the airborne oc¬
cupational exposure limits (OEL's, as seen in the EH40 documentation
[161].)
Of the 75 asthmagens and 200 skin sensitizers used in this analy¬
sis there were 18 compounds which appeared in both sets. In addi¬
tion there were a further 20 asthmagens for which skin sensitisation
had been alleged by the asthma literature but the compound had not
been cited in the skin sensitizer literature search. A logistic regression
model was created to distinguish between the asthmagens and skin
sensitizers in this set of 237 compounds. The discrimination of asthma¬
gens using this model is shown in Table 3.15. The logistic regression
model correctly identified 87% of the skin and respiratory sensitizers.
Table 3.16 displays the substructure fragments used by the model. The
model predicts 1 for a perfect asthmagen and 0 for a perfect skin sensi¬
tizer. Consequently positive (3 coefficients favour an asthmagen classifi¬
cation. Those fragments (such as the acid anhydride, the aromatic nitro
and any nitro) for which the magnitude of (3 (positive or negative) was
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Fragment (3 Standard Significance of the
coefficient Error log likelihood ratio
Aliphatic carboxyl 3.00 0.65 <0.0001
Aliphatic chlorine -0.65 0.43 0.0600
Aliphatic nitrogen 0.66 0.16 <0.0001
Aliphatic sulphur -0.63 0.41 0.0725
Acid anhydride 10.00 18.48 <0.0001
Aromatic amine -1.32 0.59 0.0091
Aromatic nitro 7.88 26.11 0.0449
Aromatic oxygen 0.72 0.28 0.0082
Aromatic sulphur 2.37 0.52 <0.0001
Isocyanate 0.95 0.59 0.0857
Nitro -7.43 26.10 0.0641
X-C-C-X (X is O or N) -0.25 0.11 0.080
Constant -2.37 0.38 —
Table 3.16: Logistic regression model to differentiate between skin and res¬
piratory sensitizers, and
Where /? is the coefficient for the fragment, S.E. is the standard error. See
Appendix D.2 for details of the values shown.
large were infrequently occurring fragments (with a large standard er¬
ror (S.E) value). Figure 3.7 shows that the model does discriminate
moderately well. The kappa value for the model is 0.62. Amongst the
skin sensitizers which were predicted as asthmagens were aminotria-
zole (predicted 0.57), dicyanodiamide (0.57), acrylic acid (0.65), benzo-
<d>-isothiazol-3-one (0.66), N,N-ethyl-4-toluene sulfonamide (0.66), Methy¬
lene bis(4-cyclohexylisocyanate (0.70 and oxacillin (0.77).
When used to predict sensitizer status of those compounds which are
believed to cause both skin and respiratory sensitisation, the equation
arising from the data in Table 3.16 produces some interesting results.
The predictions range from 0.0067 (paraphenylene diamine) to 0.9995
(phthalic anhydride). The median value is 0.175 (ethylene-diamine and











































Figure 3.7: Distinguishing Between Skin and Respiratory Sensitizers Using
Logistic Regression: Observed groups and predicted probabilities.
Each point represents 5 case chemicals. The Y axis represents predicted haz¬
ard in the range 0 (skin sensitizer) to 1 (asthmagen).
The Web-Based Model
The final logistic regression model was included in an Internet based
utility to allow access from any suitable web browser. The user has to
obtain a *.mol file to use the program but a chemical drawing pack¬
age called IsisDraw is available for non-commercial use from the URL
http: //www.mdli .co.uk/. Access to predictions is via a web form (see
Figure 3.8). The user 'pastes' in the text of the *.mol file into the form
text entry area and then clicks on the 'Submit' button. The program
returns a dynamically created web page incorporating the prediction
for that compound (see Figure 3.9).
The final model was derived from 77 asthmagens and 302 controls. It
produced a kappa value of 0.78. The equation of the model is:
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The fragment names in brackets should be substituted with the occur¬
rence frequency of that fragment in the molecule under investigation.
It should be noted that the definition of a fragment is embedded into
the programs and the names assigned here may be used as an approx¬
imate guide.
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Chemical Asthma Hazard Program
This is a slightly newer and improved version of the program
You may need to read the instructions file carefully.
Paste the contents of the MDL molfile of your query in the main text area:
03189711432D
0999 V2000
2.7564 -0.5165 0.0000 c 0 0 0 0 0 0 0 0 0 0 0
2.0067 -0.4970 0.0000 c 0 0 0 0 0 0 0 0 0 0 0
1.6149 -1.1365 0.0000 c 0 0 0 0 0 0 0 0 0 0 0
1.9728 -1.7956 0.0000 c 0 0 2 0 0 0 0 0 0 0 0
3.1145 -1.1719 0.0000 c 0 0 3 0 0 0 0 0 0 0 0
2.7279 -1.8170 0.0000 c 0 0 1 0 0 0 0 0 0 0 0
3.0932 -2.4744 0.0000 c 0 0 0 0 0 0 0 0 0 0 0
IE
(SUBMIT ) YOUR QUERY ( CLEAR ) THIS FORM
Figure 3.8: The Entry Form of Web-Based Asthma Hazard Prediction Pro¬
gram.
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Chemical Asthma Hazard Assessment
This service comes with ABSOLUTELY NO GUARANTEES.
Although every effort has been made to ensure that the results this service provides are an accurate
representation of potential asthma hazard it is not 100% effective. Consequently, even compounds
for which a very low hazard is calculated may still be capable of causing asthma. IT IS PRUDENT
TO TREAT ALL CHEMICALS AS POTENTIALLY HAZARDOUS AND IT IS
RECOMMENDED THAT USERS CONSULT OTHER SOURCES OF CHEMICAL
SAFETY DATA.
The hazard index calculated for the compound (with a molecular mass of 274.24) is:
Hazard Index = 0.6241
This molecule is very probably hazardous.
Funded by The Colt Foundation.
Silicon Graphics web server funded by The Wellcome Trust
Figure 3.9: The Result Returned from the Web-Based Prediction Program.
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3.5 Validation
The prediction models previously described have been subject to inter¬
nal validation. The study included an external validation with active
and control chemicals not used (or known about) during the creation of
the predictive model. The use of these data to validate the models is
discussed in this section.
Only eight novel asthmagens (which satisfied study criteria) were iden¬
tified from peer-reviewed literature post 1994 (See Table 3.17). So as
to avoid observer bias the external validation set was generated by a
different observer (Dr. R. Agius). The validation dataset (Dr Agius)
included 62 SWORD1 reported compounds. After rejection of repeated
compounds2, those that were not LMW organic compounds and com¬
pounds already included as asthmagens (See Table D.l), the data set
contained 38 compounds (See Table 3.18). Fourteen of the compounds
included were controls in the original dataset but were still included.
Of the twenty-five compounds originally identified as controls, nine
were rejected because they were controls in the original dataset (See
Table D.l).
Surveillance of Work-related and Occupational Respiratory Disease, a scheme
introduced in 1992 to allow chest physicians to report occupational groups and agents
with a high risk of respiratory disease (including asthma).












Table 3.17: Validation asthmagen compounds - identified from peer reviewed
literature.
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Compound Hazard Compound Hazard
Name Index Name Index
Cefotaxime 1.00 Halothane 0.00
Tetraethyl pentamine 1.00 Fenitothion 0.01
Cefuroxime 0.98 Dimethyl sulphate 0.01
Citric acid 0.92 l-Chloro-2,3-epoxypropane 0.01
Acetic anhydride 0.83 Toluene 0.02
Methacrylic acid 0.77 Diphenylmethane 0.02
Oleic acid 0.71 Dichloromethane 0.02
Pyridostigmine 0.66 Isophthalic acid 0.02
Diethylene diamine 0.58 Xylene 0.02
Codeine 0.55 Trichloroethane 0.03
Butyl methacrylate 0.49 Methylethyl ketone 0.03
Isobutyl methacrylate 0.49 Phenyl-/3-naphthalene 0.04
Hydroxypropyl methacrylate 0.43 Cyclohexanone 0.04
Dolobid 0.42 Cyanogen chloride 0.04
Ketamine 0.34 Amyl acetate 0.05
Triethylamine 0.23 Butyl acrylate 0.05
Acetaldehyde 0.14 Lindane 0.07
Dimethylformamide 0.14 Butyl phthalate 0.08
Formic acid 0.12 Acetyl salicylic acid 0.08
Table 3.18: Validation asthmagen compounds - identified from the SWORD
scheme.
The model was assessed quantitatively by calculation of a kappa value
at different threshold values. The kappa value was derived from the
hazard predictions given by the model for the compounds in the vali¬
dation dataset. A clear demarcation between the controls and the peer
reviewed asthmagens was noted with a maximal kappa value of 0.81
(threshold taken at 0.38, see Table 3.20 and Figure 3.10). The kappa
value for distinguishing between controls and asthmagens identified by
peer reviewed literature was approximately 0.7 over a range of thresh¬
old values (from 0.2 to 0.6). The SWORD data has been split to indicate
the compounds reported in SWORD which were controls in the original
(learning) dataset. Higher hazard prediction values are noted for those
SWORD compounds which were not controls in the original dataset



















Table 3.19: Validation control compounds - identified from known hazardous
chemicals.
Although enflurane was entered in as a validation control compound a liter¬
ature check on this compound revealed it had in fact been reported to cause
occupational asthma[131]. Indeed, the report predated the exclusion date of
1/1/1995 so it should have been in the original set of asthmagens.
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Figure 3.10: Scatter plot showing the predictive performance of the logistic
regression model for the validation data.
Each point represents one chemical. The horizontal lines indicate median
value. The Y axis represents predicted hazard in the range 0 (no hazard) to
1 (maximum hazard). The median values were 0.02 for the controls, 0.10 for
the all SWORD cases and 0.71 (0.43-1.00) for the peer reviewed cases. 'New
SWORD' includes only those SWORD compounds which were not controls in
the original dataset. 'Control-> SWORD' includes only those SWORD com¬
pounds which were controls in the original dataset.
controls in the original dataset (median) 0.07). The median values for
the asthmagens derived from peer reviewed literature and from con¬
trols were 0.62 and 0.02 respectively.
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Threshold 0.2 0.3 0.38 0.4 0.5 0.6
All SWORD 0.17 0.20 0.22 0.22 0.17 0.14
New SWORD 0.30 0.36 0.32 0.37 0.34 0.20
SWORD & peer 0.24 0.24 0.26 0.25 0.20 0.18
reviewed combined
Peer reviewed only 0.74 0.73 0.81 0.71 0.69 0.69
New SWORD & peer 0.39 0.41 0.42 0.39 0.30 0.25
reviewed combined
Table 3.20: Kappa (k) values for different threshold levels.
'New SWORD' indicates only those SWORD compounds which were not con¬
trols in the original dataset. 'All SWORD' includes those SWORD compounds





The three aims of this thesis were firstly, the collection of data; sec¬
ondly, the use of that data to describe (and predict) occupational chem¬
ical sensitizing hazard using chemical structure; and thirdly the use of
that relationship to stimulate novel mechanistic hypotheses. The effec¬
tiveness of this work in addressing the first two aims will be considered
first. The discussion will conclude by inferring from the observed re¬
sults mechanistic hypotheses for the pathogenesis of occupational sen-
sitisation to LMW organic chemicals.
4.1 The Collection ofData
The clinical, physiological and immunological investigation of cases of
occupational asthma (OA), coupled with occupational hygiene assess¬
ments and epidemiology provide useful information about industrial
chemical causes, and the relationship between exposure and response.
However they do not permit easy general conclusions or predictions
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about the risk that may be associated with novel chemical entities nor
do they permit a characterisation of the diversity of chemical mecha¬
nisms that lead to asthma.
The structure-activity analyses described in this work were based on
data obtained from a systematic literature search for compounds de¬
scribed as causing occupational skin or respiratory sensitisation. These
data were obtained from published medical literature found in journals
up to and including 1994. This section discusses the methods of collec¬
tion and the reliability of the data.
The literature searching had to be extensive yet still follow strict crite¬
ria to minimise any selection bias. The choice of keywords (see Table
2.1) was therefore very important. The use of terms 'manufacturing'
and 'industry' could be possibly viewed as introducing a bias towards
non-service occupations. However, the rationale for using such key¬
words was to identify as many valid occupational asthmagens as pos¬
sible. It could be argued that the control compound selection showed
a similar bias in that compounds known to be hazardous to health are
used predominantly inmanufacturing industries. There are exceptions
- workplaces such as hospitals would perhaps be under-represented as
a result of the keyword. Any use of occupation or workplace-specific
keywords to compensate for this bias could produce a greater bias. A
consequence of this was that relatively non-specific keywords and an
exhaustive scrutiny of several thousand titles and abstracts online was
necessary to identify case compounds.
The effectiveness of the literature searching for the asthmagens is dif¬
ficult to assess as there is not a definitive journal from which sufficient
references can be exhaustively checked to ensure that search tech¬
niques work well. This was important as there are only a fairly limited
number of suitable asthmagens for the study whereas it was easier to
find sufficient numbers ofskin sensitizers. For contact sensitizers, how¬
ever the journal 'Contact Dermatitis' proved suitable for such an as-
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sessment. In Volume 26 'Contact Dermatitis' 28 references were iden¬
tified which identified cases of skin sensitisation by compounds which
would be suitable for inclusion in the study. Of these 28 references,
only 6 were identified by the keywords used in the literature search. It
would have been necessary to enter occupation specific keywords to in¬
crease the sensitivity of the literature but this would have introduced
selection bias (towards those occupations). Ultimately the choice of
keywords is a balance between finding suitable numbers of compounds
given that these need to be 'manually' scrutinised, and minimising se¬
lection bias. It is therefore probable many suitable case chemicals (for
both skin and respiratory sensitizers) were not identified in this study.
One further problem associated with the use of keywords was spelling.
The spelling of sensitisation /sensitization is just one such example.
The work-around was to use both in textword searches. However this
illustrates the need for an iterative search procedure.
The quality of the collected data, particularly for respiratory sensitisa¬
tion, was extremely variable. The authors of early papers in particu¬
lar did not have the facilities to do a full investigation of chemically-
induced asthma cases. There were very few papers published covering
OA case diagnosis techniques (see Figure 3.1) and so diagnostic meth¬
ods were primitive. Furthermore the lack of computer-based journal
indexes made searching for papers on similar topics far more difficult
than it is today.
The diagnosis of causative agents by challenge testing (such as the
tray tipping method for dusts and powders used by Pepys et al. [98])
helped improve the confidence with which chemicals could be described
a cause of asthma. However many papers (including recent ones, e.g.
Gadon et al. [93]) fail to evaluate OA cases fully and thus leave some
doubt as to whether the true causative agent was discovered. The prob¬
lem arises because physicians do not always get the patient's agree¬
ment to perform challenge tests, nor do they have access to sufficient
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resources to do a full clinical work-up of each case. Therefore the con¬
fidence with which a chemical can be described as a sensitizer is based
both on the number of cases and the methods of diagnosis. This cul¬
minates in the problem that arises when there is a single case report
resulting in a chemical being attributed sensitizer status onmerely cir¬
cumstantial evidence. Over a third (31) of the asthmagens described in
the study were included on the basis of a single case report. It is likely
that a non-trivial proportion of these are misclassified.
With these considerations in mind, the diagnostic criteria for the study
do not seem strict - if the author specified a causative agent as causing
sensitisation this compound was accepted unless it failed on other cri¬
teria (see p50) or unless there were clear errors in the report. However
the study has looked specifically at compounds believed to cause occu¬
pational sensitisation in situ rather than in a laboratory. It is therefore
not unreasonable to use a clinical rather than a pathological basis for
study acceptance criteria, given that the possibility of compounds being
misclassified has been acknowledged throughout the thesis.
The data collected in this study include a number of clinically relevant
parameters such as prevalence rates, lowest observed effect concentra¬
tions1, latency and basis of diagnosis. These data are not available
for all compounds. Few published reports describe ambient workplace
levels of the chemical, those that do are subject to varying degrees of
measurement error, and in any case concentrations may differ depend¬
ing on where the sampler is placed.
Perhaps the most useful parameter to know would be the lowest ob¬
served effect concentrations for sensitisation but unfortunately this da¬
tum is rarely recorded. The portability of personal samplers must be
weighed against their lower sensitivity when compared with 'gold stan¬
dard' apparatus. The comparability of data from different samplers for
lrThe 'lowest observed effect concentration' is a toxicological term for a threshold
concentration above which toxicological effects may be observed.
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different chemicals under different work environments introduces too
many uncontrolled variables. The presence of confounding chemicals
in the work environment and the potential for synergistic mechanisms
makes accurately identifying the true hazards difficult . For this rea¬
son the study has concentrated on identifying chemical sensitisation
hazard rather than trying to assess risk.
The collection of data that was not directly used in the resulting mod¬
elling of sensitisation hazard may appear to have been unnecessary.
It was not known however whether there would have been enough of
these observations to be analysed within the logistic regression model.
Some of the data, such as the immune profile and the type of asth¬
matic response data proved useful for sorting the asthmagens into cat¬
egories of particular interest. Other data such as the 'prevalence' and
the 'method of diagnosis' details were used to indicate that the model
performed better with compounds that were unlikely to have been mis-
classified (see Figures 3.5 and 3.6).
The Role of IgE
Several interesting observations arose from the immune profile data of
the active compounds. Evidence for an IgE-mediated response was not
found with all chemicals (see Table 3.4) suggesting that mechanisms
independent of IgE may be capable of producing asthma1. The lack
of a statistically significant difference between the molecular masses
of those asthmagens for which specific IgE was identified and those in
which IgE appeared absent (see Table 3.4) suggests that mass is not the
sole determinant of whether an asthmagen elicits an IgE-dependent
immune response. In fact, even quite low molecular mass molecules
(such as phthalic anhydride, mass^;148) can elicit IgE-dependent im¬
mune responses by acting as haptens [16, 57].
1This assumes that asthma is defined in terms of disease symptoms rather than
in terms of a single immunological mechanism.
130
Asthma caused by exposure to low-molecular mass organic compounds
also displays a heterogeneity of presentation. In particular, clinically
defined OA does not always clearly fit into a classical type 1, IgE-
mediated immune response [170]. Whilst compound classes such as
the acid anhydrides clearly do fit into this mechanistic class, others
such as asthma induced by formaldehyde and ethylene diamine do
not. Furthermore, studies of the most common cause of OA, toluene
di-isocyanate (TDI), are notable for the lack of consensus with respect
to the underlying mechanism. In a review Butcher and Salvaggio state
that for TDI asthma "<20% of individuals, proved by inhalation chal¬
lenge to be reactive to TDI have IgE antibodies demonstrable by RAST1"
This may be an indication that OA may also be caused by a mechanism
independent of IgE, a possibility that has implications for the use of
predictive systems that presume asthma is caused solely by and IgE
mechanism [171].
Asthmatic Response Type
The type of asthmatic response varied (see Table 3.5) between chem¬
icals (and indeed between patients sensitized to the same chemical).
The five compounds2 for which all three response types were reported
can be considered highly reactive compounds. It is possible that these
compounds could produce asthma like symptoms by several different
methods. The isocyanates are a recognised reactive class of chemicals.
Azodicarbonamide has two carbons which are highly susceptible to nu-
cleophilic attack (due to the planar the electron withdrawing effect of
two nitrogens and one oxygen on each).
One of the unusual aspects of asthma to some low molecular weight
compounds is that there can be a delay of several hours between res-
1RAST - Radioallergosorbent Test.
2azodicarbonamide; hexamethylene di-isocyanate; toluene di-isocyanate; plicatic
acid and a trimer ofhexamethylene di-isocyanate
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piratory challenge with an asthmagen and the resulting asthmatic re¬
sponse. The occurrence of a late asthmatic response was noted with ap¬
proximately half the asthmagens. This has implications for the identi¬
fication of low molecular weight chemically induced asthma - the delay
between exposure and response can confound attempts to identify the
causal agent. In particular it is possible that many cases of asthma
may fail to be described as occupational - thus under-reporting of cases
may occur.
When the asthmatic response data and the immune profile data were
looked at together it was evident that all compounds for which IgE was
noted also exhibited a dual asthmatic response in at least one of these
cases. In addition, no compounds for which specific IgE was observed
caused solely a late asthmatic response. This opens up the possibility
that asthma to chemicals that do not cause a dual response may be in¬
voking an IgE-independent means of sensitisation. It follows that the
observation of a dual asthmatic response may strengthen the case for
suggesting a compound sensitizes via a Type 1, IgE-dependent mecha¬
nism. Acid anhydrides and reactive dyes are typical of compounds that
fall in to this latter category.
Both acid anhydrides and reactive dyes would appear to be excellent
examples of compounds which produce asthma via a Type 1 immune
mechanism. It is of interest to note that diisocyanates, the most com¬
mon and potent asthmagens, seem to less readily fall into this category,
perhaps an indication of either a different mechanism or mechanisms.
Serum IgE has however been demonstrated to be elevated in mice ex¬
posed to toluene di-isocyanate cutaneously[17].
Accompanying Symptoms
Over half the sensitising compounds had nasal symptoms as an accom¬
paniment of OA. Wheeze and cough were similarly widely reported.
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Epidemiological studies have shown that rhinitis in particular is more
common than asthma [172]. The occurrence of these symptoms amongst
workers exposed to known occupational asthmagens may be the first
signs ofOA developing.
4.2 Speciation and Structure Determination
The chemical criteria for the study - that compounds should be ofmolec¬
ular weight < 1000 and be carbon containing - were chosen to avoid
protein allergens (e.g. papain [173, p375]) and transition metal sensi-
tisers (e.g. platinum[173, p468]). Although identification of Chemical
Abstracts (CAS) Registry Number was desirable it was not essential.
It was more important to identify the correct chemical structure. Of¬
ten this identification process proceeded via a CAS Registry Number
but far too often the chemical described in a paper would refer to an
ambiguous trivial name.
Identifying the correct structure proved difficult for several compounds
as an ambiguous trivial name was given but a structure was not. An
example of this was evident in papers using the term 'alkyl' within
a structural name. Consequently the structures alkyl cyanoacrylate
and benzalkonium chloride remain ambiguous. However properly spe-
ciated representatives of these structure classes (ethyl cyanoacrylate
and lauryl dimethyl benzyl ammonium chloride) were reported else¬
where and thus were included in the study.
Six potential asthmagens were excluded because either a unique struc¬
ture could not be identified, or the true active component of a mix
was not identified, or because the compound was missed in the ini¬
tial search. These are listed in Table D.2. A full list of reported asth¬
magens (including those rejected) can be found in Appendix C.l. It is
of note that the three isomers ofmethyltetrahydrophthalic anhydride
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(MTHPA) (which were excluded because the true asthmagen amongst
them could not be identified) have the same predicted asthma hazard
(0.93). This is due to the nature of the predictor fragments in the model
not differentiating between the structures. It is possible all three iso¬
mers can cause asthma. It is worth noting that had MTHPA been in¬
cluded in the study the HOR for the acid anhydride fragment would
have been of even greater magnitude.
The constituents of the substance EPO 60 could not be used in the
analyses because the true asthmagen amongst them was not identified
(see Table D.2). The nature of the compounds and their subsequent
predicted hazards indicates that two of them, tetraethylene pentamine
and isophorone diamine have a high hazard prediction, suggesting ei¬
ther (or both) as the possible cause. (The relatively low hazard predic¬
tion for 4,4'-diamino-diphenyl methane suggests that this is less likely
the cause although it may be considered similar chemically to the re¬
ported asthmagen paraphenylene diamine (see Figure 4.1). However
the predicted hazard was also low (0.17) and the original case report
[100] on whether paraphenylene diamine is a true asthmagen may be
flawed1.
4.3 Substructure Searching
In order to relate activity to structure it was necessary to create sub¬
structure searching algorithms to identify "fragments" contained within
chemical structure. The structure of each compound in the study was
described in terms of fragment content. To achieve this the tabulation
1The diagnosis is based on patch testing of patients which merely indicates Type
IV (delayed) cutaneous rather than respiratory sensitization. In addition the work¬
ers were exposed to fur and so their asthma symptoms may have been due to animal
dander allergy. Finally, the results in asymptomatic asthmatic patients ofpositive in¬
halation challenge tests to paraphenylene diamine and hydrogen peroxide may have
been due to the increased airway hypersensitivity exhibited by asymptomatic asth¬
matics.
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Figure 4.1: The structures of paraphenylene diamine and 4,4'-diamino-
diphenyl methane.
of fragment content was automated computer programs (see Appen¬
dices A and B). Although commercial software was available that pro¬
vided this functionality, the restrictive nature of commercial software
would have prevented the creation of a stand-alone hazard prediction
program. Since the creation of a practical hazard prediction system
was intended from the outset (see Section 1.5) the decision was made
to write the required software. This brought considerable program¬
ming complexity into the study and while it will be dealt with briefly
here in the discussion it did account for a considerable amount of the
work.
The computer programs could describe compounds in one of two frag¬
ment types (see Figure 2.6). The Methods section describes in detail the
two types of fragments used (type 1 and type 2 fragments, p62). The
selection of fragments was not objective and consequently this may be
seen as a source of bias. Whilst the use of a validation dataset helps
to counter such a criticism it would have been preferable to have had
a systematic (thus objective) method for generating all possible frag¬
ments1 for the dataset. It should be noted that even if implemented,
1Although an additional requirement would be that the fragments would have to
occur a minimum number of times in the dataset to be of statistical importance.
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automatic fragment generation would probably only occur for Type 1
fragments.
The main advantage of type 1 fragments is the speed with which new
fragments can be added. The fragment is simply drawn in a chemical
drawing program and a * .mol connection table file [159] (see Figure-
2.4) created. A fragment dictionary of compounds can be entered into
a database and from this a * . sdf file [159] (see Figure 2.5) created.
The disadvantages of type 1 fragments are that searching for them is
computationally intensive and that they do not allow 'wild-card atom
or bonds to be specified.
Type 2 fragments are useful for the same reasons. A particular atom
node in the fragment can be specified to match any one of a list of el¬
ements and similarly a bond may be allowed to match irrespective of
whether it is saturated or not. Furthermore, because type 2 fragments
are hard coded into the program (as subroutines), the search algorithm
can be optimised to match against the least frequently occurring ele¬
ments of the fragment first. In this way fewer comparisons are made
before a match can ruled out. However because type 2 fragments are
hard coded, adding new fragments is technically demanding; this is the
main disadvantage of type 2 fragments.
The coding of the type 2 fragment algorithms chronologically preceded
the coding of the type 1 fragments. This occurred because the algo¬
rithm to implement a general (type 1) substructure search is far more
complex and fits into the set of problems known as NP complete [174],
Consequently the algorithm involves exhaustive and recursive search¬
ing to find the result. The complexity of the algorithm can be guessed
from attempting to formalise the steps one would take to determine
whether one compound is contained within another. In order to do this,
one must match every atom of one compound against every atom of the
other1. If an atom matches then all its neighbouring atoms need to be
1There are some screening algorithms which can be used to avoid some of the
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matched. In addition, the bond type between them needs to be checked.
All these checks have to be repeated as the matching progresses from
bond to bond (and back).
There are further difficulties. There is a need to know when to stop:
for cyclical searches checks need to be made to prevent infinite looping
around a ring. In addition many structures have symmetry and so
checks need to be made to ensure that matches are not occurring on
the same atoms in reverse. The solution to this was to identify how
many times a fragment could find itself in itself then correct the result
accordingly.
4.4 Previous Structure-Activity Studies Of
Chemical Asthma Hazard
To date most methods for predicting chemical asthma hazard have
been based on animal models and a number of methods exist in vivo
to screen compounds for OA hazard [175]. Several animal models have
been developed in the last few years, perhaps the most promising of
which is the use of a cytokine fingerprinting technique in the mouse
[176]. These methods however tend to be expensive, time consuming
and specific to only one or two classes of compound. There was a clear
need for a cheaper, more rapid method of identifying potential respira¬
tory sensitizers prior to their being introduced into the workplace.
Current quantitative structure-activity approaches to investigating the
relationships of respiratory sensitisation have been limited to using
small datasets of sensitizers [177]. A qualitative chemical structure-
based hazard prediction exists for sensitising compounds in the form
of a rule-based, expert system (DEREK)[178], The use of systems such
exhaustive searching.
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as DEREK relies on an "expert" judgement including mechanistic as¬
sumptions and the determination of empirical rules.
More recently Karol et al. published a structure-based model for pre¬
dicting skin sensitisation hazard which does not assume a mechanism
of activity [179]. Only 39 "respiratory chemical allergens", based on
animal studies as well as human data, were used in the study. These
case chemicals were compared with compounds which did not cause
skin sensitivity.
The identification and selection of the active and control compounds for
all studies may affect the validity of the results. Our selection of con¬
trols was based on agents that are known or presumed to be hazardous
and to which there is significant occupational exposure to warrant the
setting of exposure limits. It is therefore probably more appropriate
than random selection of chemicals (regardless of human exposure) or
assuming (as Karol et al. did [177]) that skin and respiratory sensiti¬
sation are mutually exclusive and that skin sensitizers represent ade¬
quate controls for respiratory sensitisation. In particular the require¬
ment that an active compound be a documented cause of human occu¬
pational respiratory sensitisation rather than suspected from screens
in vivo was fundamental to the study. The use of chemical cases de¬
fined on the basis of animal models may introduce a bias in favour of a
particular pathological mechanism.
4.5 Clustering
Clustering was the first method used to differentiate between com¬
pounds of differing activities by means of their structural information.
It provided a useful learning tool but it was dismissed as a suitable
modelling option early in the study. For this reason there is no cluster
analysis of the differences between skin and respiratory sensitizers.
This section will look briefly at the role of clustering
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Clustering techniques involve the classification of entities by descrip¬
tors to produce groupings based on similarity. Several methods can be
employed and these fall in to two distinct categories: hierarchical; and
non-hierarchical. The method chosen in this study was the divisive
hierarchical Guenoche method [166] based on the results of a prelimi¬
nary study performed by Dr G. Downs. This preliminary study looked
at several other clustering methods but as a cluster program had to
be written from the general algorithm (see p70) it was decided to set¬
tle on one clustering method. The Guenoche method was chosen after
considering the results of Table 3.7, and following discussion with Dr
Downs.
Clustering does not directly provide a method of predicting a biologi¬
cal activity for chemicals. However, an activity for a compound may
be inferred by association. That is, it is inferred that the activity of a
compound will be similar to that of the other compounds with which it
shares a cluster group. Calculating a chi-squared statistic for the clus¬
ters based on this method results in very significant p values as the
number of clusters is increased. These p values in isolation are how¬
ever a poor and inappropriate measure of overall model performance.
The results of the preliminary cluster analysis are summarised in Ta¬
ble 3.7.
For the complete asthmagen and control dataset clustering was per¬
formed using either 'presence or absence' of descriptors - the binary
method, or using the occurrence frequencies of the descriptors - con¬
tinuous method (see p69). A schematic representation of clustering
process of each is given in Figures 3.2 and 3.3. Several of the clusters
appeared to be strongly predictive of either control or asthmagen sta¬
tus. Cluster 5 of the binary method was one such cluster. All 31 of
the compounds in cluster 5 were controls and 29 of these contained at
least one halide (fluorine, chlorine or bromine). This is worth noting as
the possibility that halide may confer a 'protection' against a compound
being an asthma hazard will be mentioned again.
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Despite a few interesting clusters, overall the clustering approach proved
unsatisfactory for a number of reasons. Firstly, it is not easy to identify
the important discriminating variables nor quantify their contribution,
so little mechanistic insight can be gained from this method. In addi¬
tion, the use of excess (redundant) descriptors may occur and this is to
be avoided [158]. The use of such redundant descriptors increases the
possibility that, for the learning set, the differentiation will occur by
chance. The descriptors will work for the learning set (by chance) how¬
ever when the same method is applied to a novel set the descriptors
will not be applicable. Increasing the number of clusters may improve
kappa but at a cost. The resulting smaller clusters are more likely to
contain solely asthmagens or solely controls however the smaller size
may preclude a cluster being statistically significant. Once clusters
with very few or even single entities start to form the value of cluster¬
ing for activity inference becomes suspect and the kappa value mean¬
ingless. It would be very simple to use cluster analysis to produce N
clusters were N is also the number of entities used. Such a procedure
would produce a prediction system that was perfect for the learning set
but incapable of providing reliable predictions for new compounds.
Consequently clustering is perhaps a poor choice for predictive mod¬
elling but it may still have a role for classification of molecules into
mechanistic groupings. It was not however considered further in this
study.
4.6 Hazard Odds Ratios
The Hazard Odds Ratio (HOR), in providing a relatively simple mea¬
sure of a fragment's contribution to activity, also provides an excellent
fragment screen prior to use in multivariate analyses (such as regres¬
sion). In any multivariate study it is desirable to maintain a suffi¬
ciently greater number of observations than variables to avoid vari-
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able redundancy [158], For QSAR1 were the scope exists for the use
of large numbers of variables (from fragment dictionaries), HOR's pro¬
vide a means to individually screen out those variables most likely to
be redundant. This approach was used to great effect with the type 1
fragments (see p2.3) and resulted in the identification of a number of
potentially important fragment variables (see Table 3.8).
One of the most interesting outcomes of this study is that the HOR's
for some fragments, for example aliphatic amine groups, markedly in¬
crease with occurrence frequency (see Table 3.11). Furthermore the
HOR's for single occurrence of chemical substructures such as imine
fragments, aliphatic or aromatic amines or carbonyls were not sig¬
nificant at the 5% level. However two or more occurrences of these
fragments was significant. It appears that a single occurrence of cer¬
tain hazard fragments in a compound may not be sufficient to pose an
asthma hazard. Instead some degree of bi- or poly-functionality ap¬
pears to be required. These results support the hypothesis that chem¬
icals that are bi-or poly-functional (i.e. have cross-linking) are over
represented within the set of known respiratory sensitizers. Such an
hypothesis implies a threshold of two active groups, and that a single
fragment is associated with low hazard. The results could however be
explained by arguing that whilst a single fragment was insufficient to
produce a statistically significant HOR it is still hazardous but only to
a fraction of the hazard of two fragments.
Whilst the evidence for a cross-linking mechanism in OA is not totally
conclusive it should be noted that no reports of isocyanates causing
asthma are due to mono-isocyanates. This could however be a reflection
of infrequent use since bi-functional compounds find wide industrial
application precisely because of their cross-linking properties. How¬
ever one of the notable features of isocyanate asthma is the fact that
many studies fail to identify evidence for an IgE-mediated sensitisation
mechanism [8, 85, 180] in every patient. This is not to say it has not
Quantitative structure-activity relationships.
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been shown in some cases, rather, that it is frequently absent despite
the presentation of OA. If a cross-linking mechanism is responsible for
some asthma cases, it may be for those atypical cases where IgE has
not been demonstrated. Indeed, the implication is that di-isocyanates
may be able to cause asthma by two distinct mechanisms.
There are several other compounds which can be viewed as potential
cross-linkers. Although formaldehyde (h2c=0) has a structure which
appears mono-functional, in aqueous environments it acts as a diol
(ho-CH2-OH). One of the uses of formaldehyde is as a fixative and achieves
this by cross-linking. No IgE has been determined in cases of formalde¬
hyde asthma. Similarly, glutaraldehyde (which is a bi-functional alde¬
hyde) is also a cross-linking agent. Again no IgE has been determined.
Neither compound gave rise to an immediate asthmatic response type
which would be expected with a Type I IgE-mediated asthma. Inter¬
estingly the carbonyl group is one of those for which two fragments are
significantly hazardous whereas one is not (see Table 3.11).
Amines also seem to be far more hazardous in pairs (see Table 3.11).
The bi-functional chemical ethylene diamine is an asthmagen yet the
mono-functional ethyl amine is not. Furthermore no IgE has been
demonstrated for ethylene diamine induced asthma and the response
type in a case where bronchial provocation testing was performed was
'late dual' [181]. Another curious feature of ethylene diamine is that it
is better known as a skin sensitizer [182],
Amechanistic hypothesis based on the need for chemical bi-functionality
is not inconsistent with immuno-biochemistry of antibody-allergen recog¬
nition. Theoretically, immunologically recognisable epitopes may arise
from a normally non-antigenic proteins if it is cross-linked. Whether
this is important through intra- or inter-molecular cross-linking re¬
quires further investigation. However, amongst the compounds for
which cross-linking may be important, are the poly-amines and the
polyisocyanates which can cause sensitisation without any observed
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IgE response. This contrasts with the more classical hapten-induced,
IgE-mediated response seen with the anhydrides. Yet the sensitisa-
tion due to these compounds is certainly an allergic response. The
possibility remains that bi-functional sensitizers may sensitize via a
non-classical IgE mechanism such as by causing membrane damage or
cross-linking of a cell surface receptor. A possible candidate cell would
be the mast cell. Indeed, to activate mast cells, IgE 'cross-binds' two
cell surface receptors. These seem unlikely hypotheses at present since
they need to be reconciled with the allergic-like nature of the disease
and the observation that certain people are more susceptible than oth¬
ers. However if airway insult by irritant gases or disease is important
as an initiation process in asthma pathogenesis, then a sensitisation
may be the result of chemicals reaching the normally unexposed air¬
way sub-epithelial cells.
Anhydride Asthma
One of the few fragments for which a single occurrence is significantly
associated with reported OA hazard is the acid anhydride fragment.
Although acid anhydrides contain two carbonyl groups and in this re¬
spectmay be considered bi-functional, these are not independent. When
one reacts, perhaps to form an amide with a lysine (that is, an amine
side chain) residue of a protein, the remaining carbonyl group becomes
part of a carboxylic acid. Carboxylic acids tend to be more chemically
stable, so although these groups could form esters with other proteins
this is unlikely. Published evidence from elsewhere has suggested that
acid anhydride asthma is caused by the anhydrides acting as haptens
and rather than cross-linkers [183, 57]. Anhydride asthma is typical of
Type 1 (immediate hyper-sensitivity) IgE-mediated asthma.
One of the arguments used to suggest that anhydrides work by cross-
linking is the fact that acetic anhydride is not an asthmagen1 because
1According to the SWORD scheme acetic anhydride has been reported as an asth-
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it cannot bridge - when it undergoes hydrolysis the molecule splits into
two acetic acid molecules. This argument is weak. It could equally be
argued that an acetyl group makes a poor epitope when compared with
the phenyl group of phthalic anhydride. So acetic anhydride may be
reactive enough to attach to proteins, but in doing so does not make the
host protein antigenic. Therefore it is unlikely that cross-linking and
bi-functionality have a role to play in the pathogenesis of anhydride-
mediated OA.
Protective Fragments
The use of substructure hazard odds ratios may also identify 'protec¬
tive' substructures, that is, chemical substructures which may preclude
a chemical from presenting an OA hazard. This study showed that the
presence of aliphatic chlorine in a structure was associated with a re¬
duced likelihood of that structure being a reported cause of OA. This
may be due to increased toxicity1 of chloro-compounds (such that other
adverse effects occur at lower exposures than required for sensitisa-
tion).
Odds Ratios To Differentiate Skin and Respiratory Sensitizers
When odds ratios were used to differentiate between asthmagens and
skin sensitizers the carboxylic acid fragment appeared to be associ¬
ated with a compound being an asthmagen. The carboxylic acid frag¬
ment had a large and highly significant trend favouring its presence in
asthmagens (see Table 3.13). The question ofwhat role the carboxylic
acid group plays in asthmagens arises again. However the reason for
magen however all SWORD reports should be considered as requiring confirmation.
Acetic acid however has been reported in published literature as causing asthma
[184],
Hhat is toxicity other than asthma toxicity.
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the high significance could be that the fragment is excluded or rare
amongst skin sensitizers because the carboxylic acid is a hydrophilic
group. Skin sensitizers are typically more hydrophobic than respira¬
tory sensitizers [185]. This would explain why the fragment did not
appear so significant in the differentiation of asthmagens from the con¬
trol dataset (which included skin sensitisers, see Figure 2.1).
The presence ofoxygen but not nitrogen confers an increased likelihood
that a compound is an asthmagen rather than a skin sensitizer (see
Table 3.12) which may be mostly due to the acid anhydride and the
carboxylic acid fragments having large HOR's. When these fragments
are taken into account, there is probably a fairly even spread of oxygen
and nitrogen compounds across both skin and respiratory sensitizers.
Perhaps one of the factors that determines whether a compound is a
skin or respiratory sensitizer (or both) is not how it reacts but where
it reacts, and this may be a function of its water solubility. Given that
skin is generally a dry environment whereas the respiratory tract is
moist this might seem a reasonable hypothesis. Polar compounds on
the skin will not be readily absorbed and are easily washed away. Lipid
soluble compounds however will be quickly absorbed and are difficult to
wash away. In contrast, the moist environment of the airways favours
the polar compounds.
4.7 Logistic Regression
The principle advantages of using logistic regression are that variables
can be assessed for a statistically significant contribution before inclu¬
sion and and that allowance is made for variable interaction. Thus
the contribution made by fragments may be different when they are
considered in combination as opposed to in isolation.
The use of the stepwise logistic regression facility within the SPSS pro¬
gram was considered appropriate since this work falls into both the
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exploratory and the predictive categories described by Menard [186],
Briefly, all the fragments entered into the logistic regression modelling
program start in the model. Variables are then removed on the basis
that their contribution to the model is not statistically significant. The
significance of the likelihood ratio was used in preference to the Wald
statistic to determine whether a fragment stayed in the model because
some of the fragments, for example the isocyanate fragment were rare
but occurred exclusively in active compounds. That is, the presence
of the fragment guarantees activity but its absence does not preclude
activity.
The first logistic regression model (see Table 3.14) distinguished be¬
tween asthmagens and controls with a kappa (based on the validation)
of 0.74. When internally validated (using the learning dataset), the
logistic regression model appeared to be better at predicting asthma
hazard for those compounds for which the confidence in their being
asthmagens was greatest. Compounds for which diagnosis was based
on respiratory challenge (the definitive diagnostic method) (see Figure
3.5) or those compounds for which two or more cases of asthma had
been reported were in general better predicted (see Figure 3.6).
Analysis of the misclassified compounds highlights some key points
about the model. It is possible that if we assume the model is a good
predictor of hazard, the misclassified compounds represent data out¬
liers. Consequently, by looking at misclassified active compounds such
as styrene, ethylene oxide and chloroxylenol we may be looking at
asthma caused by an atypical mechanism. Equally, for the misclas¬
sified controls, such as methacrylic acid the model might be correctly
identifying compounds with true sensitising hazard which have not yet
been reported as such. For example the control compound methacrylic
acid is predicted as a hazard (0.77) and it should be noted that methyl
methacrylate is an accepted respiratory sensitizer and acrylic acid is
a suspected one [108]. Another curious false positive was strychnine
(0.74). It can be postulated that strychnine may be a potential sensi-
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tizer but because of its reputation as a poison, exposure to it may have
been more tightly controlled than compounds of equivalent but less no¬
torious toxicity1.
The correlation between hazard predicted and confidence of original
active classification, poses the question ofwhether it would have been
valid to classify compounds by potency or prevalence for use in a linear
regression analysis. There are good reasons why this would be a less
effective approach to modelling. The first reason to avoid using activity
coded as a continuous variable is that the data on which to base this
value is simply not available for all compounds. Secondly, the 'basis of
diagnosis' and the 'absolute prevalence' may be measures of the con¬
fidence with which asthma causality can be assigned - the true value
is either 'yes' or 'no' - but combining the two into a meaningful scale
would require a great deal of subjectivity. It would be difficult to decide
how many separate cases of sensitisation diagnosed on circumstantial
evidence are equivalent of one case diagnosed with a double blind res¬
piratory challenge.
There are several notable substructure fragments absent from the lo¬
gistic regression model variables (see Table 3.14) which had signifi¬
cant HOR's (see Table 3.10). For example neither the carboxylic acid
fragment nor the ethanolamine backbone are represented in the lo¬
gistic regression model variables (Table 3.14). This suggests that the
HOR's for these fragments occurred because these fragments contained
other substructure fragments, such as oxygen atoms or nitrogen atoms.
When corrected for the presence of these smaller fragments the ethanol amine
fragment would no longer appear independently significant.
The most striking feature about the fragments in the first logistic re¬
gression model (see Table 3.14) is the magnitude of the aldehyde and
ketone fragments. The aldehyde fragment has a large negative contri¬
bution (-12.21) which may seem unexpected given that formaldehyde
JNot asthma toxicity.
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and glutaraldehyde are amongst the asthmagens. The standard errors
for these two fragments are also large, indicating that these fragments
are may have been included by chance. However the p-0.0043 value
of log likelihood ratio for the ketone fragment suggests it has an im¬
portant role in the model. The definition of the ketone fragment does
not preclude it matching the same carbonyl group as the aldehyde frag¬
ment. It is notable that the magnitude of the aldehyde and ketone (3
coefficients (-12.21 and 14.36 respectively) are ofsimilar magnitude but
working in opposition. It is probable that the important carbonyl sub¬
structure in determining asthma hazard is a carbonyl fragment that is
not an aldehyde.
The acid anhydride, isocyanate and acrylate groups have large positive
(3 coefficients and small standard errors (relative to their (3 coefficients).
This suggests that these compounds not only influence whether a com¬
pound is hazardous but may also be decisive. That is, their presence
alone is enough to determine whether they are predicted active or not.
The model also feature three halide atoms, chlorine (aliphatic and aro¬
matic), bromine and fluorine. These all appear to have a 'protective'
effect with respect to asthma hazard. This 'protective role' has been
also been noted with the clustering and the HOR's. It may be appro¬
priate in future work to combine these fragments into a single generic
halide type 2 fragment.
The model might find application after further validation for the pur¬
pose of hazard prediction - thus if a novel chemical entity were to
score a value of say higher than 0.3 or 0.5 it may be cause for concern
if it were not being used in a manner in which exposure was strin¬
gently controlled and prospective health surveillance practised. Cau¬
tion should be advised however with respect to identifying 'safe' com¬
pounds. It is apparent that the hazard posed by some known (but now
less commonly reported) respiratory sensitizers such as para-phenylene
diamine are poorly predicted by the model.
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The Model to Differentiate Between Skin and Respi¬
ratory Sensitizers
The role of the skin dataset has been throughout this study been rel¬
egated to a lesser importance than the task of identifying respiratory
sensitizing agents. This is partly due to the difficulties of finding suit¬
able controls for skin sensitizers. However the role of the skin dataset
was always intended to allow comparisons between skin and respira¬
tory sensitizers, rather than to attempt to predict skin sensitizing haz¬
ard.
A number of compounds cause both types of sensitisation. When a
prediction is calculated for these compounds by the skin model they
appear across the full range between skin and respiratory ends of the
scale (see Figure 3.7). It has been suggested that skin and respira¬
tory compounds are functionally divergent [56] and perhaps mutually
exclusive. Whilst this may be the case in laboratory studies, the situ¬
ation in the workplace is more complex. Models of sensitisation which
are based on a divergence of skin and respiratory sensitisation may fail
to identify hazardous chemicals because they presume a single mecha¬
nism of sensitisation.
4.8 Validation
The validation of the model by an independent set of chemicals is a key
factor in evaluating this work. It alone is sufficient to make this work
unique amongst structure-activity studies in this field. Similar studies
such as those of Karol et al. [177] and Payne et al. [178] have failed to
validate their systems independently.
The validation of the model utilised two sources of reported respiratory
sensitisers. The first and perhaps less reliable source (due to the ab-
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sence of a quality-control element) was the reports to SWORD1 [163],
The second source were the data published after 1994. This second
source was probably more reliable since a usual prerequisite of publi¬
cation is that the report be peer-reviewed, thus reducing the the pos¬
sibility of speculative speciation of compounds as asthmagens. This is
a possible explanation of why the model performed better when vali¬
dated by published data rather than SWORD data. A possible source
of bias that would effect the kappa values for the SWORD data is the
fact that several of these chemicals were originally used as controls.
Chemicals 'promoted' from control to SWORD status are subject to a
bias that results from their originally contributing to the model defini¬
tion of'control'. Allowance was made for this fact (see Figure 3.10 and
Table 3.20) and it was very apparent that predictions were (not surpris¬
ingly) poorer for those SWORD compounds which had been controls in
the original learning dataset. The poor fit of some of the SWORD data
to the model is a cause for concern since it suggests that either the
model doesn't work or that the SWORD scheme produces unreliable
data.
The nature of a scheme such as SWORD is such that false positives are
less of a concern than false negatives. One possible false positive in
the SWORD scheme list of suspected asthmagens is halothane (hazard
index 0.00). Personal communicationwith an experienced anaesthetist
and an absence ofpublished reported cases ofhalothane induced-asthma
despite exposure under a clinical setting of both patients (high concen¬
trations) and anaesthetists (low but frequent concentrations), suggests
halothane may be such a false positive. (It is however of interest to
note that another inhalation anaesthetic, enflurane was found to have
been reported to cause OA in 1976 [131]).
Further limitations of the SWORD Scheme exist. Some compounds in
1Surveillance of Work-related and Occupational Respiratory Disease, a scheme
introduced in 1992 to allow chest physicians to report occupational groups and agents
with a high risk of respiratory disease (including asthma).
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the SWORD list appear twice: methylene chloride and methylene chlo¬
rine probably refer to the same compound; likewise, Trichlorethane (as
spelled) and trichloroethylene also seem to refer to the same compound.
The verification of a compound's asthmagenicity by a suitable respira¬
tory challenge test is not required for a compound to be included in
the SWORD Scheme. Furthermore the unique identification of a single
chemical cause is often missing with the result that the suspect agent
is not correctly speciated.
Despite the limitations of the validation data the model performed well,
particularly for the peer reviewed data where the kappa value of 0.81
is extremely satisfactory (see Table 3.20). Although this is based on
relatively few validation compounds it is nonetheless comparable ifnot
better than existing methods which have not been as rigorously val¬
idated. Consequently the Internet based prediction system that has
been developed directly from the programs used and the logistic re¬
gression models created provides the first readily available prediction
systems for chemical asthma hazard.
If discrete judgements on activity are to be made a suitable threshold is
required. Normally a threshold of 0.5 is used but the data here exhibits
a kappa value consistently around or above 0.7 (see Table 3.20) for
thresholds in the range 0.2 to 0.6. One reason why a value of below
0.5 is more appropriate in this study is because the model is based on
data using a considerably greater number of controls than asthmagens.
Perhaps a more convincing reason for choosing a lower threshold is
that there is less to be lost in predicting a compound active when it is
not than missing a true sensitizer. Taking this into consideration, the




Several compounds not included in the validation have recently been
reported to cause occupational hazard. They were identified via a Med-
Line search so only the title and abstract has so far been consulted.
However because testing of the a compound takes minutes and costs
very little, hazard predictions can generated with ease. The model pre¬
dictions for these compounds are given below:
Compound Hazard
Of these the model would have identified cefmetazole, diethanol-amine
and l,2-benzisothiazol-3-one as very hazardous compounds. Morphine
would be considered a hazard as it is greater than 0.3. It has predicted
poorly for the other two compounds but this is not necessarily a prob¬
lem. Since the methodology has been validated, the model could be
updated to use newly diagnosed asthmagens.
This work provides a solid foundation for several follow up studies.
Firstly there is now a case for updating the predictive model to include
those occupational asthmagens identified (from case reports in peer
reviewed journals) since 1994. This would provide the most up to date
basis for assessing novel chemical structures for asthma hazard.
Cefmetazole [Fracchia et al., 1996]
Ninhydrin [Piirila et al., 1997]
Isothiazolinone [Bourke et al., 1997]
Diethanol-amine [Piipari et al., 1998]
l,2-benzisothiazol-3-one [Moscato et al., 1997]









The selection of fragments for the logistic regression could be improved.
For example the creation of a generic halide type 2 fragment would pool
the chlorine, fluorine and bromine (and possibly iodine) atoms to see if
the protective effect is general across the Group 7 elements.
A second way in which the model could be improved is to validate it
against work currently being undertaken to assess chemical asthma
hazard by in vivo assays [171]. This would provide an interesting cross-
validation of two techniques. Any agreement between the two methods
would provide strong evidence for the acceptance of both the structure-
based prediction system and the mechanisms underpinning the labo¬
ratory work. Conversely, any areas of disagreement would highlight
areas were laboratory animal-based studies cannot be reconciled with
the available human data.
The data used for this study may also be suitable for the creation of a
neural network based predictive model. One drawback of using neural
nets is the difficulty faced in identifying the relevant data input. This
precludes (or at least makes very difficult) the inference of underlying
chemical mechanistic hypotheses.
A more long term goal might be to apply the methods used here in a
slightly different area. It may be possible to apply the technique suc¬
cessfully to identify carcinogens by structure alone in a more general




It is evident from the reviewed literature that clinically defined occu¬
pational asthma cases may arise in the absence of any evidence of an
allergic mechanism. That is, asthma occurs without an identifiable im¬
munological pathway being invoked. Consequently a distinction needs
to be made between 'occupational allergic disease hazard' and 'occupa¬
tional asthma hazard'. The former implies an immunological process
whereas the latter implies merely that a process leading to asthma1 is
involved.
It is evident therefore that the original null hypothesis (see pl5) which
states:
The potential of a chemical to cause occupational allergic
disease cannot be predicted from structure alone.
was overly optimistic. This work does not provide a basis for reject¬
ing this null hypothesis. Had the null hypothesis been more conser¬
vative such that it stated 'The occupational asthma hazard posed by
1Defined clinically by symptoms.
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a chemical cannot be predicted from structure alone' then there would
be grounds to reject it. Unfortunately null hypotheses cannot be made
retrospectively!
Despite failing to reject the null hypothesis this work provides much
that is useful such as (1) the novel methodology, (2) the general obser¬
vations about the types of chemicals that pose an asthma hazard, (3)
the comparison between skin and respiratory sensitisers and (4) the
production of a prototype hazard prediction system.
1) The chemical case-control methodology is an effective and novel ap¬
proach to quantitative structure-activity relationships. The decision to
pursue an observational rather than a mechanistic approach was cru¬
cial factor in the validity of this work. The results are independent of
any a priori assumptions of mechanism and are based on a statistical
approach. The results can therefore be understood in the absence of
immunological mechanistic knowledge. Furthermore the results are
better than those obtained in other studies.
2.a) Cross-linking may play a key role in an IgE- independent asthma
mechanism. A number of chemical groups such as amines, aldehydes
and isocyanates, when present twice or more in a chemical, are suf¬
ficient to make that chemical an asthma hazard. The target of the
cross-linking is not known but mast cell IgE receptors are likely candi¬
dates.
b) Acid anhydrides probably do not cause sensitisation by cross-linking.
Acid anhydride-induced asthma is typical of a Type 1 immediate hyper¬
sensitivity asthma and as such probably causes asthma by an IgE me¬
diated response rather than by a cross-linking mechanism.
c) The presence of halogens (fluorine, chlorine and bromine) in a com¬
pound is associated with a reduced asthma hazard. This may be a
result of other toxic effects preventing workers being exposed to sensi¬
tizing concentrations.
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3.a) Skin and respiratory sensitizers are not mutually exclusive. Al¬
though differences exist between skin and respiratory sensitizers there
is considerable overlap. The same compound may cause both types of
sensitisation. The functional differences may arise from differing phys¬
ical properties, particularly water solubility. Compounds causing occu¬
pational asthma tend to contain more hydrophilic fragments.
4) A simple, working prototype hazard prediction system has been cre¬
ated. As a working hazard prediction model, the findings of this work
can be quickly, cheaply and easily compared with those of other studies
and of emerging case reports. Therefore there is a ready mechanism for
extending the validation of the predictive model presented here and, as
required, improving upon it.
There are twomajor weaknesses of this workwhich need to be acknowl¬
edged here and remedied in future studies: (1) the subjective selection
of descriptor fragments; and (2) the lack of 3-dimensional information
in the description of chemicals.
1) The non-objective selection offragments may have biased the results.
Objectively selected fragments were not used because of the difficulty
in generating the exhaustive list of possible fragments. The choice
of descriptor fragments may therefore have been biased towards frag¬
ments known to be present in compounds that pose an asthma hazard.
The successful validation procedure suggests that this does not sub¬
stantially invalidate the findings however this bias must be considered
in the overall interpretation of the results. If the difficulty in generat¬
ing an objective set of fragment descriptors were to be overcome, then
the use of such a fragment set should provide a more robust methodol¬
ogy-
2) The descriptor fragments used were too small to contain topograph¬
ical (3D) chemical structure information. This study is notable for
not employing 3D structure information in the chemical descriptions.
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Molecular shape is important for many if not most biochemical inter¬
actions, consequently the use of topological descriptors in this study
may be a cause for concern. The immunological mechanisms involved
in antigen recognition are highly dependent upon shape as well as
charge and hydrophobicity so one might expect that descriptors dis¬
criminating between sensitisers and non-sensitisers would require to
have recognisable shape properties. However the descriptors (small
sub-structure fragments) used in this study may be too small to influ¬
ence the overall shape of the molecules from which they are derived.
If the descriptors are considered too small to influence overall shape
or form, then the implications are either (i) that the results described
in this work arise by chance, or (ii) that shape is not the major deter¬
mining factor of the biological endpoint described in this work. If the
former (i) is the case then this work is relegated to being merley a data
collecting and methodology developing body of work. If the latter (ii)
is the case then it follows that what this work describes is not aller¬
gic respiratory sensitisation hazard, but occupational asthma hazard.
This is still consistent with the hypothesis that bifunctionality rather
than overall form seems to determine hazard. If the compounds are
not antigenic in themselves but rather they create antigenic features
with host molecules then the descriptors fragments need not contain
large amounts of 3D information since they are markers of reactivity
and perhaps hydrophilicity/availability not shape.
In many ways the descriptors used in this study are not solely indica¬
tors of shape or reactivity. The study relates the presence of chemical
descriptors to a process that also involves inhalation and absorbtion as
factors influencing the biological endpoint of asthma symptoms. Given
that the study models a multi stage-process it is not surprising that
the conclusions drawn from the apparently significant fragments are
general rather than specific ones.
It is possible that by incorporating chemical structure descriptors based
upon shape rather than atomic connectivity better results could be ob-
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tained. However there is a limit to the usefulness of such an approach
in this study. As the 3D complexity of a descriptor increases, its fre¬
quency of occurrence and therefore its potential to be of statistical sig¬
nificance drops.
Overall the conclusion is that the chemical case-control methodology
employed in this thesis can be useful if applied to heterogeneous and
poorly understood chemical-structure activity relationships. The method¬
ology cannot provide detailed mechanistic insights but may lead to use¬
ful general observations. The results and the predictive model provided







In 'C' there is a declaration type termed a structure. These 1 structure's
are a method for representing data in an ordered and logical man¬
ner. Since an ambiguity between chemical structure and program¬
ming structure could arise, the latter will always be referred to in
typewriter font.
molecule.h
molecule.h is not a subroutine as such but this file contained the
structure definition for the software coding of molecule connectivity.
Two types of structure are defined: the molecule structure; and
the atom structure. It is worth looking at these structure defini¬
tions closely to understand how chemical structures were represented
within the software. The structure of an atom is described in Fig¬
ure A. 1
The role of the variables listed in Figure A.l a is:
sym contains a string containing the element symbol.
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struct *atoms{
char sym[3]; /* The atomic symbol */
int mask; /* A mask used by some routines */
int aromatic; /* Marked if atom is in aromatic ring */
int valence; /* Default valence for element */
int n_bonds; /* number of atoms bonded to atom */
int *bonded_atom; /* Structure array of n_bonds atoms */
int *bond_type; /* Structure array of n_bonds bond types
Figure A.l: 'C' structure representation of an atom.
mask contains a masking flag variable used by some routines.
aromatic contains a flag indicating whether the atom is part of an
aromatic ring.
valence holds an integer giving the normal valency for that atom.
n_bonds contains the number of atoms this atom was bonded to.
*bonded_atom contains an array of n_bonds integers corresponding
to atom number of the bonded atom in the molecule.
*bond_type contains an array of n_bonds integers corresponding to
the bond types between the atom and the n_bonds bonded
atoms.
The structure of a molecule is described in Figure A.2. It can be seen
that any instance of a molecule contains a variable that holds the lo¬
cation of the molecule name; *name; an integer n_atoms telling how
many atoms are present in the molecule; an array *atom of n_atoms
addresses to the constituent atoms; and a flag integer variable invalid.
Using this representation each molecule could be represented in such a
way that all the topological information, including bond and atom types








/* Flag variable for some routines */
/* Molecule name, if one exists */
/* Number of atoms in molecule */
/* Array of pointers to each atom */
} ;
Figure A.2: 'C' structure representation of a molecule.
readmol()
This routine reads a molecule in from a standard chemical connection
table (MDL *.mol or *.sdf file formats [159] These connection tables
contain a list of all atoms followed by a list of all bond pairs between
atoms (see Figure 2.4). The readmolO routine interprets an *.sdf file
into a 'c' molecule structure (see Figure A.2). These 'c' structures are
dynamically allocated memory structures which exist only as long as
they are needed.
molfree()
This routine frees the dynamically allocated 'C' molecule and atom
structures.
strseek()
This general purpose routine reads forward through a file until it reaches
a specified string, which it reads and leaves the current file position as
the character immediately following the string.
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saturate()
This routine is used to add the implied hydrogens to a structure. In
an * . sdf file (see Figure 2.4) the hydrogens are not usually explic¬
itly stated but are instead implied by the unused valency. The routine
saturate () scans molecules previously read in by readmol () and
recalculates the atom and bond content to explicitly include the hy¬
drogens. This is needed because the same molecule, coded twice with
implied hydrogens in one and explicitly stated hydrogens in the other
would mean the former could be seen as a substructure of the latter
but not vice versa.
findfrag()
The routine f indf rag () determines whether one structure is a subset
of a second. Since some hydrogens might be explicitly labelled in the
*
. sdf file of the first structure which are only implied in the second,
the second molecule should first be processed with the saturate ()
routine.
To find if two files contain identical structures, both should be pre-
processed with saturate (), and f indf rag () should be run to see if
the first molecule is a substructure of the second and if the second is a
substructure of the first. If both these calls to f indf rag () return true
then the molecules are identical.
The routine f indf rag () has a few internal checks to ensure that sym¬
metrical substructure fragments are only found once. Consider ethane
as fragment. It can find itself in itself two ways. The problem is multi¬
plied sixfold with benzene - benzene can be superimposed upon to itself
12 ways (not six because it can flip). To resolve this problem, the rou¬
tine first calculates a denominator from the number of times the query
substructure fragment can be found within itself. Then the number of
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occurrences of the query fragment in the target structure was calcu¬
lated. This result when divided by the above mentioned denominator
gives a fragment occurrence frequency for the fragment in the target
structure properly corrected for the any symmetry.
aromatise()
This routine calculates for each atom in a molecule whether it is ad¬
jacent to or contained within a six membered aromatic ring. If so the
aromatic flag in the 'c' atom structure is labelled true. The routine
does not pick up atoms which are adjacent to the class of aromatic 5-
membered rings. Consequently this limited definition of the term aro¬
matic is specific to this work.
atom_count()
This routine takes an atomic symbol (e.g. CI) and searches for the
number of occurrences of that symbol within a compound.
gethazard()
This is the key routine in the programs that predict a hazard index for
compounds. The coefficients for each fragment are entered into the file
containing this routine (gethazard. c). If one wishes to change the
coefficients or even add in new type 2 fragment routines this is the file
to edit.
Specialised Routines for Specific Fragment Subset
The type 2 fragment searching routines are shown in Table A.l. A
computer coded representation of the molecular structure being stud¬
ied is fed to the subroutine and it returns the number of occurrences
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of the type 2 fragment in the molecule. The term arom implies that at
least one of the atoms of the fragment either is, or is attached to, an
atom that has its aromatic flag (set by the aromatise () routine) set
to true. The number of aliphatic (i.e. non-aromatic) occurrences of a
fragment is calculated from the difference between the total number
of occurrences of the fragment and the number of occurrences of the
fragment deemed aromatic.
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1°, 2° or 3° amine fragments
anhydride fragments
any double-bonded atom pairs
any triple-bonded atom pairs
aromatic C=0 fragments
aromatic 1°, 2° or 3° amine fragments
























The accompanying CD-ROM has been created to contain both software
and data described in this thesis. The CD-ROM uses an iso9660 file-
system and so should be accessible from the vast majority of operating
systems. Please bare in mind the following notes:
1. The contents of the CD-ROM remain the intellectual property of
the author and The University of Edinburgh. For further details
read the file LICENSE.txt in the root directory.
2. For a full description of the contents of the CD-ROM read the file
CONTENTS.txt
3. For general details relevant to each directory read the file README.txt
in that directory.
4. Useful third-party software has been included in the programs \other
directory. The conditions of use of the software should be read
carefully before use.
Use of the CD-ROM is at the end-user's risk. Although every effort has
been made to ensure the CD-ROM is virus free users should scan the
disk before opening it.
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The following data and programs are available on the CD-ROM:
1. Hazassess - the web based asthma hazard prediction program.
2. batchpredic t - can predict hazards for multiple compounds (from
an *.sdf file)
3. cluster - a program to generate clusters from a table of property
data.
4. qstruct - a program to fragment all the compounds in one *.sdf
file using type 1 fragments (stored in another fragment dictionary
*.sdf file)
5. fingerprint - a program to fragment all the compounds in one
*.sdf file using type 2 fragments
6. kappa - a small routine to calculate a kappa value given the four
number entries to the 2x2 table.
7. Asthma and skin databases in proprietary format.
8. Asthma and skin databases in readable *.sdf text format.
9. Web based access to the database information.






Compounds listed in Table C.l are those low molecular mass organic
chemicals reported or suspected of causing asthma. Several aremarked
with question marks, indicating that the published evidence was not
sufficient for the compound to be included in the analyses. However,
in an attempt to be a definitive sensitive list of published asthmagens
these suspect compounds have been included for completeness.
Table C.l: LMW Organic Asthmagens
CAS Number Compound and Reference
514-10-3 Abietic acid / Colophony[172, 59]
64-19-7 * Acetic acid [184]
79-10-7 * Acrylic acid [108]
957-68-6 7-Amino-cephalosporanic acid [114]
111-41-1 Amino-ethyl ethanolamine [92, 90]
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121-25-5 Amprolium hydrochloride [143]
123-77-3 Azodicarbonamide [138, 139]
8001-54-5 * Benzalkonium chloride [82]
69-57-8 Benzyl penicillin [113]
I l,3-bis(cyanatomethyl)-cyclohexane prepolymer BIC
17095-24-8 Black GR Reactive Dye (BK-5) [64, 187]
2425-06-1 Captafol [110]
13466-78-9 3-Carene[137]
1390-65-4 * Carmine [72, 73]
X Ceftazidime
15686-71-2 Cephalexin [13]
127-65-1 Chloramine-T [83, 84, 85]
55-56-1 Chlorhexidine [86]
88-04-0 Chloroxylenol [81]
12238-08-3 Cibachrome Brilliant Scarlet 32 Reactive Dye [63]
51481-61-9 Cimetidine [121]





108-01-0 Di-methyl ethanolamine [23]
117-81-7 Dioctyl phthalate [124]
* Direct Black [68]
49745-95-1 Dobutamine Chlorohydrate [188]
101-68-8 Diphenylmethane Di-isocyanate [155, 156, 153]
51811-44-0 Drimaren Brilliant Blue K-BL Reactive Dye [63]
13838-16-9 * Enflurane [131]





























Ethylenediamine [95, 96, 91]







Hexahydrophthalic anhydride[48, 47, 52]











•k Lanasol Yellow [67]
•k Lauryl dimethyl benzyl ammonium chloride [81]





Methyl cyanoacrylate [104, 103, 105, 108]
* Methyl hexahydrophthalic anhydride [51]
Methyl methacrylate [102, 103]





































Phenyl glycine acid chloride [125]
Phthalic anhydride [41, 40, 42]
J Piperacillin sodium
Piperazine [97, 91, 98] hardener
Pyromellitic dianhydride [40]
Red-BBN Reactive Dye [64]
Rosin / plicatic acid [189]
Salbutamol [132]
Sodium iso-nonanoyloxybenzenesulphonate [88, 116]
Spiramycin [116, 117, 118]
Styrene [102, 134, 135, 136]
Sulphathiazole [127]
Tetrachloro-isophthalonitrile [109]
Tetrachloro-phthalic anhydride [43, 44, 45, 40, 46]
Tetracycline [190, 119]
* Tetraethylene-pentamine[101]
l-(5-Tetrazoly)-4-guanyl tetrazene hydrate [141]




Trimellitic anhydride [42, 47, 40, 48, 40, 49]
l,3,5-tris-(6-isocyanato-hexyl)-<l,3,5>triazinane-2,4,6-trione [192, 193]
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Key: ★ indicates possible asthmagen but rejected, omitted or missed
from the original asthmagen dataset.
| indicates asthmagen in the validation set and derived from published
literature from 1995 onwards.
f indicates asthmagen in the validation set but derived from the SWORD
Scheme (see p57).
C.2 Skin Compounds
A number of the citations (particularly those in foreign language jour¬
nals) in this appendix were consulted by title and abstract only. The
chemical property data was obtained from various sources, principally
the Beilstein Online Database [194], the Merck Index [195] and the
Aldrich Catalogue [196]. Synonyms are delimited by a semi-colon.
1. Diphenyl Guanidine [197]
2. Ethyl alcohol; Ethanol [198]
3. Disulfiram; Tetraethylthiuram disulfide [199]
4. Propylene oxide [200]
5. Metanil yellow [201]
6. Cyanamide [202, 203]
7. Ethylene diamine; 1,2-diaminoethane [204, 205, 206, 207, 208, 209, 210,
211]




11. Tylosin [215, 216, 217, 218]e
12. Triforine [219]
13. Trifluralin [220]
14. Benefin; Benfluralin [220]
15. Captan; 2-trichloromethylsulfanyl-3a,4,7,7a-tetrahydro-iso-indole-l,3-dione
[221, 222, 223, 224, 225]
16. Benzydamine [226, 227]
17. 2-<N-ethyl-4-amino-3-methyl-anilino>-ethanol; CD4-colour developer [228]
18. Aziridine cross-linker cxlOO; Ethylene-imine; [229, 230]
19. CD-2 Colour developer; N',N-diethyl-2-methyl-p-phenylene diamine [228]
20. Propranolol [231, 232]
21. Thimerosal; Ethyl[2-mercaptobenzoato(2-)-0,S]-mercurate-(l-) sodium
[233, 234, 225]
22. Triethylenetriamine; Trientine [209]
23. Limonene; 4-isopropenyl-l-methyl-cyclohexene; p-mentha-l,8-diene; [233,
235]
24. Cresyl glycidyl ether; 2-p-tolyloxymethyl-oxirane [206]
25. N-<l,3-dimethyl-butyl>-N'-phenyl-p-phenylenediamine; Santoflex 13 [236,
237]
26. Triglycidyl isocyanurate; l,3,5-tris-oxiranylmethyl-<l,3,5>triazinane-2,4,6-
trione [238, 239, 240, 241]
27. Diamino-diphenyl methane [242, 243, 155, 238, 153]s
28. 2-hydroxy-ethyl methacrylate; methacrylic acid-<2-hydroxy-ethyl ester>;
2-methyl-acrylic acid 2-hydroxy-ethyl ester [238, 244, 245, 246]
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29. Benzene-l,4-diamine; p-Phenylenediamine [247, 248, 249, 250, 251, 234,
252]r
30. N-ethyl-4-toluene sulfonamide; N-ethyl-4-methyl-benzene-sulfonamide
[253]
31. 4-tolyl diethanol-amine; N,N-bis-<2-hydroxy-ethyl>-p-toluidine [253]
32. Isophorone diamine; 3-amino-methyl-3,5,5-trimethyl-cyclohexylamine [254,
255, 256]
33. p-Toluenesulfonyl Chloride; Tosyl Chloride [257, 258]
34. Benzoyl peroxide[259, 260, 261]
35. Diethylenetriamine; Nl-(2-amino-ethyl)-ethane-l,2-diamine [262, 209,
210, 263]
36. Bupirimate; dimethyl-sulfamic acidmono-(5-butyl-2-ethylamino-6-methyl-
pyrimidin-4-yl) ester [264]
37. Benomyl [223]
38. 4-N,N-dimethyl-amino-benzene diazonium chloride [265]
39. Thiourea; Thiocarbamide [265, 266]
40. Methyl methacrylate [267, 268]
41. Falcarinol; heptadeca-l,9(Z)-diene-4,6-diyne-3-ol [269]
42. 2-methyl-isothiazol-3-one [270, 271, 272, 273]




47. Benzalkonium Chloride [277, 150, 278]
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48. Diphenylmethane di-isocyanate; bis-(4-isocyanato-phenyl)-methane; 4,4'-
methanediyl-bis-phenyl isocyanate [155, 156, 153]
49. Glutaraldehyde [150, 151, 152]
50. Kathon 930; 4,5-dichloro-2-octyl-isothiazol-3-one [279]
51. 3-(dimethylamino)-propylamine [280]
52. Alachlor; 2-chloro-N-(2,6-diethylphenyl)-N-methoxymethylacetamide [281]




56. Chloro-hydroxyimino-acetic acid ethyl ester; Oxalic acid-2-ethyl ester-1-
chloride-l-oxime [286]
57. Benzo<d>isothiazol-3-one; [287, 288, 289, 273, 290, 291]
58. Nicergoline [292]
59. Cyclohexanone; Keto-hexamethylene [293]
60. Toluene di-isocyanate; 2,4-di-isocyanato toluene; 2,4-tolylene di-isocyanate;
TDI; Nacconate 100; 4-methyl-l,3-phenylene di-isocyanate; [153]
61. Hexamethylene di-isocyanate [153, 154]
62. Ethyl-(ethoxymethylene)-cyanoacetate; 2-cyano-3-ethoxy-acrylic acid ethyl
ester [294]
63. Triphenyl phosphite [295]
64. carvone; p-mentha-6,8-dien-2-one [296]
65. 2-Mercaptobenzothiazole; Mercaptobenzothiazole; Captax; [297, 298]
66. Dimethyl cyano-carbonimido-dithioate; N-cyano-dithio-carbonimidic acid
dimethyl ester [299]
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67. Minoxidil; 3-oxy-6-piperidin-l-yl-pyrimidine-2,4-diamine [300]
68. Dazomet; 3,5-dimethyl-<l,2,4>-thiadiazinane-2-thione [301]
69. 4-diazo-N,N-diethylaniline; 4-(diethylamino)benzenediazonium [302, 303]
70. Resorcinol; 1,3-benzenediol [248]
71. Pyrogallol; 1,2,3-Benzenetriol [248]
72. Nitroglycerin; 1,2,3-Propanetriol-trinitrate [304, 305]
73. Azaperone [306]
74. 1,1,1-Trichloroethane [307]
75. Tripropylene glycol diacrylate [308]
76. Trimethyl-oxiranylmethyl-ammonium chloride; Glycidyl trimethyl am¬
monium; [309, 310, 311]
77. Glycerol mono-thioglycolate [312, 313, 314]
78. 4-Chloro—7-nitro-benzofuran [315]
79. Mitomycin-C [316]
80. 2,2-Bis-(4-oxiranylmethoxy-phenyl)-propane; DGEBA; 2,2-bis-(4-glycidyloxyphenyl)-
propane [317, 318]
81. C,C'-m-phenylene-bis-methylamine; m-xylylenediamine; 3-aminomethyl-
benzylamine [319]
82. Methacrylic acid; Methacrylate; [244]
83. Acrylic acid; Acrylate; [244]
84. Kitasamycin [320]
85. Midecamycin (Al) [320]
86. Ethyl thiourea [213]




90. Amprolium hydrochloride [321]
91. Nitrofurazone [322, 323]
92. Olaquindox [324, 325]
93. Bisphenol A; Bisphenol A glycerolate (1 glycerol/pheno) diacrylate; [326,
327]
94. Styrene [328]
95. Butylated hydroxy-toluene [329]
96. Thiamin; Vitamin B1 [330]
97. 1,2-dichloro-propane [331]
98. l,3-Dicyclohexyl-carbodiimide[332, 333]
99. Chloramine-T [334, 335, 152]
100. Dimethoate [223]
101. Carbaryl [223]
102. Thiram [223, 336]
103. Propineb [223]
104. Propachlor [223, 337]
105. Metham Sodium [223]
106. Tetrafluoroterephthalonitrile [338]
107. TFX diamine; l,4-bis(aminomethyl)-2,3,5,6-tetrafluorobenzene; [338]
108. Tri-(ethylene glycol)-dimethacrylate [339]
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113. Oct-2-ynoic acid methyl ester [345]
114. Non-2-ynoic acid methyl ester [345]
115. para-Aminophenol[234]
116. or^o-Aminophenol [234]
117. Quinophthalone [234, 346]
118. Procaine hydrochloride; Novocaine [234, 232]
119. N,N-diethyl-beta-chloro-ethylamine [347]
120. Crystal Violet lactone [348]
121. Folpet [224]
122. Captafol; Difolatan; [224]
123. Ranitidine [349, 350]
124. N,N'-bis-<2,alpha-dichloro-benzylidene>-hydrazine [351]
125. diazonium compound [352]
126. 2-hydroxyethyl-acrylate [353]
127. Trimethylolpropane triacrylate [354, 355, 356, 357, 358]
128. Diglycidylhexahydrophthalate; Cyclohexane-l,2-dicarboxylic acid dioxi-
ranylmethyl ester [157]
129. Phenyl salicylate [359]
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130. Aminotriazole [360]
131. Ortho-benzyl-parachlorophenol; Clorophene [361]
132. 5-chloro-2-methyl-isothiazol-3-one; Kathon CG; [272, 273, 225]
133. (1-methylethylidene) bis <4,l-phenyleneoxy(2-hydroxy-3,l-propanediyl)>
bismethacrylate; 2-methyl-acrylic acid 2-hydroxy-3-<4-(l-(4-<2-hydroxy-
3-(2-methyl-acryloyloxy) -propoxy>-phenyl)-l-methyl-ethyl)-phenoxy>-propyl
ester [362]
134. Dodecyl-di-(aminoethyl)-glycine; Dodicin; Tego 51; Ampholyt-G [362,
154, 363, 364, 365, 366]
135. Chemical Mace; omega-chloroacetophenone; alpha-chloroacetophenone
[367, 368, 369]
136. Aminoethyl-ethanolamine [370]
137. Neomycin [371, 372]
138. Streptomycin [372, 373]
139. 1-Naphthyl iso-thiocyanate [374]
140. 2-{5-dimethyl-aminomethyl-furan-2-ylmethylsulfanyl)-ethylamine [375,
350]
141. Mercaptoacetic acid [376]
142. Tetra-(ethylene glycol)-diacrylate [377, 378]
143. 1,3-dibutylthiourea [379]
144. Tetryl; Nitramine; N-methyl-2,4,6,N-tetranitro-aniline [380]
145. TNT; 2,4,6-Trinitro-toluene [380]
146. bis-acryloylamino-methane; [245, 381, 382]
147. Epichlorhydrin [383]
148. Methylene bis(4-cyclohexylisocyanate) [384, 385]
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149. Tetrachloroisophthalonitrile [386]
150. Pentaerythritol triacrylate [356, 357, 387, 358]
151. 1,6-Hexanediol diacrylate [356, 358]
152. 4-tert-Butyl-catechol [388]
153. 5-amino-4-chloro-2-phenyl-2H-pyridazin-3-one; chloridazon; pyrazon; [389]
154. Sorbitan Monooleate; Span(R); Tween(R) [390]
155. 2-hydroxymethyl-2-nitro-propane-l,3-diol [385]
156. 2-bromo-2-nitro-propane-l,3-diol; bronopol [385]
157. Methyl-dithio-carbamic acid [391]











166. 3-<(4-methyl-piperazin-l-ylimino)-methyl>-rifamycin; Rifampicin [397]
167. diphenyl-cyclopropenone; 2,3-diphenyl-cycloprop-2-enone [398]







171. Spiramycin 1 [218, 117]
172. Penethamate BP [218]
173. Methyl isothiocyanate [402]
174. Eugenol [403, 232]
175. Aminophylline [232]
176. Chlorpromazine hydrochloride [232]
177. N-methyl-para-aminophenol [404]
178. 2-hydroxy-3-naphtoic acid-o-aniside [404]
179. N-acetoacetyl-benzylamide [404]
180. Monosulfiram [405]
181. N-isopropyl-N'-phenyl-p-phenylenediamine [406, 237, 407]













189. 4-tert-butyl-phenol; Para-tert-butyl-phenol. [413]
190. Sodium amidotrizoate; Diatrizoate sodium [414]
191. Pentaerythritol tetrakis-3-mercaptopropionate [415]





195. Nonylphenol ethoxylate; nonoxynol-6 [418]
196. Squaric acid dibutyl ester [419]
197. Naphthol AS; 3-hydroxy-naphthalene-2-carboxylic acid anilide; 3-hydroxy-
<2>naphthoic acid anilide; 3-hydroxy-naphthalene-2-carboxylic acid pheny-
lamide [420]
198. 4-vinyl-l-cyclohexene diepoxide; l,2-epoxy-4-oxiranyl-cyclohexane; 3-oxiranyl-
7-oxa-bicyclo<4.1.0>heptane [421]
199. Bromo-<4-methoxy-phenyl>-acetic acid ethyl ester [422]















































































Allyl alcohol Allyl-2,3-epoxypropyl ether
Azinphos-methyl Benomyl
Benzene Benzenethiol
































Dimethyl formamide Dimethyl phthalate
Dimethylamine Dioxathion





Ethyl acrylate Ethyl benzene








Isobutyl acetate Isopentyl acetate













































































































Compound Validation Reason for
Category Exclusion
Iodomethane Control Control in original dataset
Cumene Control Control in original dataset
Chlorobenzene Control Control in original dataset
2-Ethoxyethanol Control Control in original dataset









Control in original dataset
Control in original dataset
Control in original dataset
Asthmagen in original dataset
Asthmagen in original dataset
Asthmagen in original dataset
Asthmagen in original dataset
Asthmagen in original dataset
Table D.l: Compounds rejected from the validation.
A number of compounds were rejected from the validation dataset provided by
Dr Agius. The rejection ofvalidation compounds might be considered a source
of experimenter bias so the justification for their exclusion is listed here.
D.2 Interpretation of Logistic Regression
Tables
The initial interpretation of Tables 3.14 and 3.16 may lead one to the
conclusion that certain variables should not be included because the
standard error of /3 is of a larger magnitude than the variable's coeffi¬
cient /?. The interpretation of the standard error should be that it gives
a measure of the possible range of values the coefficient /3 could take
but should not be the determinant of whether the variable should be
included in the model. Indeed, when the independent variable predicts
too well then the problem of complete separation occurs [186]. This
leads to very large coefficients and standard errors. The inclusion of
a variable in the model is based upon a statistically significant reduc¬
tion in the ability of the model to predict accurately. This is implicit in
the use of the backward log likelihood statistic as the determinant of
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Compound Name Hazard Reason for exclusion from
analysis
Acetic acid (see Fig¬ 0.83 This compound was missed.
ure Entered and used as a con¬
trol
and in the later analyses
but a report of asthma was
found [184]
Acrylic acid 0.15 This compound is a sus¬
pected asthmagen [108]
which was used as a control
in the analysis.
Methyl-tetrahydro- 0.93 Mixture of three isomers.
phthalic anhydride All have the same calculated
asthma hazard.
Methyl-hexahydro- 0.93 Not a full paper.
phthalic anhydride
Tetraethylene pent- 1.00 Constituent of EPO 60,
amine Lambourn et al. described
occupational
asthma caused by EPO 60
[101]
Isophorone diamine 0.81 Another constituent of EPO
60 [101].
4-4' diamino-di- 0.22 Another constituent of EPO
phenyl methane 60 [101].
Enflurane 0.00 Paper missed due to lack of
'occupational'
or equivalent keyword [131].
Table D.2: Possible asthmagens excluded from the study.
Several potential asthmagens were excluded from the study. As this might be
considered a source of experimenter bias they are documented here complete
with the reason for their exclusion.
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HOR Hazard Odds Ratio (see page 73)
IgE Immunoglobulin E
IgG Immunoglobulin G
LMW Low Molecular Weight
MDL Molecular Design Limited (see http: / /www.mdli . co . uk/)
MIDAS Manchester Information Datasets and Associated Services (see http: / /ww






Note: References cited in the main text have been properly consulted.
References cited in the appendices may have only had the title and ab¬
stract reviewed in order to confirm they refer to cases of occupational
sensitisation. This is particularly the case where several reports re¬
fer to a single chemical. They are included here in order to provide a
comprehensive listing for the chemical case data.
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